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Abstract 
 
The accessory protein Nef of human immunodeficiency virus type 1 (HIV-1) has 
long been known to enhance the infectivity of HIV-1 progeny virions. The 
multipass transmembrane proteins serine incorporator 3 (SERINC3) and 
SERINC5 were recently identified as novel antiviral proteins that restrict HIV-1 
infectivity. Nef enhances HIV-1 infectivity by removing SERINCs from the plasma 
membrane, which prevents their incorporation into progeny HIV-1 virions. To 
exploit this potent intrinsic antiretroviral factor for potential therapy development, 
it is critical to explore the determinants in SERINC5 that govern its 
downregulation by Nef and its restriction on HIV-1 infectivity. Here I report that 
the ability to inhibit HIV-1 infectivity is conserved among vertebrate SERINC5 
proteins, whereas the sensitivity to downregulation by Nef is not. However, a Nef-
resistant SERINC5 became Nef-sensitive when its intracellular loop 4 (ICL4) was 
replaced by that of Nef-sensitive human SERINC5. Conversely, human 
SERINC5 became resistant to Nef when its ICL4 was replaced by that of a Nef-
resistant SERINC5. In general, ICL4 regions from SERINCs that exhibited 
resistance to a given Nef conferred resistance to the same Nef when transferred 
to a sensitive SERINC, and vice versa. I demonstrate that human SERINC5 can 
be modified to restrict HIV-1 infectivity even in the presence of Nef. Moreover, by 
generating chimeras between SERINC5 and SERINC2, which does not exhibit 
antiretroviral activity, I demonstrate that SERINC5’s inhibitory function, unlike the 
 iv 
sensitivity to Nef, requires the participation of more than one region. Helix 4 and 
extracellular loop 5 (ECL5) of SERINC5 are both required for the potent 
restriction of HIV-1 infectivity. In contrast, a large amino-terminal portion of 
SERINC5 is not required for its antiretroviral activity of SERINC5. The 
determinants in ECL5 disperse throughout the loop. Furthermore, the ECL5 of 
SERINC5 is a hotspot region that determines the Env-dependent antiretroviral 
activity of SERINC5.  
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Chapter I 
Introduction 
 
 
Since the first case of acquired immune deficiency syndrome (AIDS) in the 
US was reported in 1981, HIV-1 has infected worldwide more than 70 million 
people and caused the death of about 35 million people (WHO 2017). Thanks to 
the development of antiretroviral therapy (ART), the HIV-1 infection can be 
controlled and is considered as a clinically controllable chronic disease. Potent 
combination ART provides remarkable control of viral loads, and restores 
immunity in patients. Even with dramatic reduction in morbidity and mortality, 
there were still 36.7 million people living with HIV/AIDS at the end of 2016. 1.0 
million people died of HIV-1-related illnesses in 2016 (UNAIDS). There is no cure 
or vaccine yet. If ART treatment is interrupted, viral rebound occurs due to the 
establishment of latently infected resting CD4+ T cells (Chun et al., 1997; Finzi et 
al., 1999). Taken together, a better understanding of host-viral interactions and 
immune defenses is required. In addition to innate and acquired immune 
responses, humans have evolved specific antiviral factors that are constitutively 
expressed and already active at the first virus-cell interaction. This dissertation 
investigates the inhibition of HIV-1 by a novel host antiretroviral factor, SERINC5, 
and its counteraction by the HIV-1 viral protein Nef. This introductory chapter 
prepares the background on HIV-1 and the logic for this thesis research.  
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HIV-1 genomic structure and virion structure 
 
HIV is a lentivirus containing two copies of positive-sense single-stranded 
viral RNA. The HIV-1 genome encodes the major structural and non-structural 
proteins shared with other replication-competent retroviruses (Figure 1.1A) 
(Freed, 2001). The long terminal repeats (LTR), composed of U3, R and U5 
regions, are at the 5’ and 3’ end. The gag, pol and env genes, from the 5’ to 3’ 
ends of the genomes, encode the essential structural and enzymatic proteins. 
Their translation products are initially synthesized as polyprotein precursors, 
which are subsequently processed into viral proteins incorporated into the mature 
virions. The gag gene encodes the precursor protein Pr55Gag, which is cleaved 
by the viral protease (PR) into the mature Gag proteins matrix (MA or p17), 
capsid (CA or p24), nucleocapsid (NC or p7), p6, as well as two spacer peptides 
(SP), p1 and p2. The 160-kd Gag-Pol precursor is cleaved by the viral PR and 
gives rise to three individual pol-encoded enzymes, which are PR, reverse 
transcriptase (RT), and integrase (IN). The envelope (Env) glycoprotein 
precursor, gp160, is encoded by the env gene. Unlike the Gag and Pol 
precursors, gp160 is processed by a cellular protease, which result in two 
glycoproteins. One is the surface (SU) Env glycoprotein gp120, and the other is 
the transmembrane (TM) glycoprotein gp41. They are organized into trimeric 
spikes displayed on the surface of the virion. They are non-covalently 
associated. Gp120 contains five relatively conserved domains (C1–C5) and five 
 3 
variable regions (V1– V5). Gp41 is composed of the ectodomain, transmembrane 
domain and the cytoplasmic tail. 
In addition to the gag, pol and env genes, HIV-1 encodes the essential 
regulatory proteins Tat and Rev, as well as the accessory proteins Vif, Vpr, Vpu, 
and Nef. Tat is essential for transcriptional elongation from the HIV-1 promoter, 
while Rev is required for the transport of viral RNA from the nucleus to the 
cytoplasm. Vif, Vpr, Vpu, and Nef were named “accessory”, because they are not 
required for virus replication in tissue culture. However, they are critical elements 
of combating host intrinsic immunity. The function of accessory viral proteins will 
be discussed in the following part of this chapter.  
 The virion packages all of the components required for infectivity. MA 
forms the discontinuous outer matrix shell, lying underneath the lipid membrane 
of mature virions. It attaches to the lipid membrane via an amino-terminal 
myristoylated and positively charged segment. Env forms trimeric spikes on the 
surface of the virion. The CA protein forms the conical mature capsid, also called 
the core. The capsid approaches the matrix closely at both ends. In the center of 
the core is the NC protein, which covers the RNA genome. RT, PR and IN are 
essential enzymatic proteins that are incorporated into virions as well. tRNAs and 
other small host RNAs are not shown in the model (Figure 1.1B).  
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Figure 1.1. HIV-1 genomic structure and virion structure. 
A. Organization of the HIV-1 genome.  
B. Model for a mature HIV-1 virion. 
Reprinted and adapted with permission Springer Nature (Freed, 2001).  
A 
B 
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HIV-1 replication and antiretroviral drug therapy. 
 
 In addition to its own viral proteins, HIV-1 exploits the cellular factors to 
promote its replication in the target cell. HIV-1 enters susceptible cells by utilizing 
the cell surface receptors, which determine the viral host range. HIV-1 encodes 
the enzymatic proteins to reverse transcribe and integrate the viral genome into 
host chromosomal DNA, but this process also depends on cellular transport 
machinery. The essential regulatory proteins Tat and Rev together with host 
transcription factors and spliceosomes regulate viral gene expression at the 
transcriptional and posttranscriptional level.  
 An understanding of the molecular biology of the viral life cycle provides a 
basis for antiretroviral drug development. HIV-1-specific antiretroviral drugs were 
initially given as monotherapy. The administration of a cocktail of antiretroviral 
drugs revolutionized the treatment of HIV-1 infection (reviewed in Arts and 
Hazuda, 2012). Current combination therapy, known as HAART (highly active 
antiretroviral therapy), effectively suppresses the plasma HIV-1 viral load to 
undetectable levels, which also restores the immune system in advanced HIV-
infected patients (Autran et al., 1997; Lederman et al., 1998). HAART avoids the 
selection of virus clones bearing drug-resistance mutations that preexist in the 
viral quasi-species before initiating therapy (Coffin, 1995). The challenge for 
future antiretroviral drug therapy is to simplify the regimen to fewer drugs with 
higher potency and longer duration.  
 6 
  A better understanding of the virus replication cycle has advanced 
mechanistic-based drug discovery. Based on their molecular mechanism, current 
US Food and Drug Administration (FDA)-approved drugs can be divided into six 
classes, which are fusion inhibitors, coreceptor antagonists, nucleoside-analog 
reverse transcriptase inhibitors (NRTIs), non–nucleoside reverse transcriptase 
inhibitors (NNRTIs), integrase inhibitors and protease inhibitors (Arts and 
Hazuda, 2012). Figure 1.2 illustrates the replication cycle of HIV-1 and the 
targets of antiretroviral drugs from various classes. In this chapter, I will review 
the molecular mechanism of each step in viral life cycle, with the focus on the 
targets for ART.  
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Figure 1.2. Distinct classes of antiretroviral drugs target different steps of 
the HIV-1 replication cycle in a CD4+ T cell. 
The numbered steps and inhibitors targeting each step are as followed: 
1. Entry—attachment inhibitors, chemokine receptor antagonists, and fusion 
inhibitors 
2. Reverse transcription—NNRTI, NRTI 
3. Integration—integrase inhibitors 
4. Transcription—inhibitors of Tat-TAR interaction 
5. Virus assembly and production—inhibitors to block virion maturation 
6. Protease processing—protease inhibitors 
Reprinted and adapted with permission from Cold Spring Harbor Laboratory 
Press (Arts and Hazuda, 2012).  
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HIV-1 entry  
 The process of HIV-1 entry into a susceptible cell represents the first step 
in the viral replication cycle. It is characterized by a series of conformational 
changes of the viral surface glycoproteins upon engagement of the receptor CD4 
and of a coreceptor. A clearer understanding of the molecular mechanism of HIV-
1 entry has advanced the development of neutralizing antibodies and of 
antiretroviral drugs that inhibit viral entry. The mechanism and categories of 
neutralizing antibodies will be discussed in Chapter III.   
 
The molecular mechanism of entry. 
Following adhesion of the virus to the host cell, the entry of HIV-1 into host 
cells involves the binding of the gp120 Env glycoprotein to its primary receptor, 
the CD4 glycoprotein (Maddon et al., 1986; McDougal et al., 1986) (Figure 1.2). 
A starting point leading to the discovery of the HIV-1 receptor CD4 was the 
observation that AIDS is primarily related to a defect of the helper-inducer T 
lymphocytes (Schroff et al., 1983). Further studies showed that HIV-1 
preferentially infects CD4+ T cells in vitro (Klatzmann et al., 1984). Incubation of 
CD4+ T cells with certain monoclonal antibodies against CD4 blocks HIV-1 
binding, and the HIV-1 Env glycoprotein can be coprecipitated with CD4 
(McDougal et al., 1986). The normal function of CD4 is to enhance T-cell 
receptor (TCR)-mediated signaling. The structure of CD4 in complex with the 
core of gp120 has been solved. Env interacts with the CD4 binding site in gp120 
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(Kwong et al., 1998), causing rearrangements of V1/V2 and subsequently V3. 
The variable loops V1-V3 are lying at the apex of the Env trimer, and play critical 
roles in viral entry and immune evasion (Hartley et al., 2005). The conformational 
changes within gp120 upon CD4 binding result in the exposure of a binding site 
for the chemokine coreceptors, CCR5 or CXCR4 (Kwong et al., 1998).  
The first coreceptor for HIV-1 entry to be identified was the G protein-
coupled chemokine receptor CXCR4, which is preferentially used by laboratory-
adapted HIV-1 isolates (Feng et al., 1996). Soon thereafter, several groups 
identified CCR5, a receptor for the b-chemokines RANTES, as the coreceptor for 
primary HIV-1 strains (Alkhatib et al., 1996; Deng et al., 1996; Doranz et al., 
1996; Dragic et al., 1996). A 32 bp deletion within the coding region of ccr5 
results in a frameshift and generates a non-functional receptor (Dean et al., 
1996; Liu et al., 1996; Samson et al., 1996). Individuals homozygous for the 
deletion are profoundly resistant to R5-tropic primary HIV-1 viruses (Dean et al., 
1996; Liu et al., 1996; Samson et al., 1996). The coreceptor usage of HIV-1 
classifies HIV-1 strains (Berger et al., 1998). Isolates that use CCR5 are termed 
R5 viruses. These include the majority of primary HIV-1 isolates, including so-
called macrophage-tropic strains of HIV-1. Strains that solely use CXCR4 are 
termed X4 viruses, but these are relatively rare in infected individuals. More 
common are isolates able to use both co-receptors, which are termed R5X4 
(Berger et al., 1998). Isolates of HIV-1 from early in the course of infection 
predominantly use CCR5 for infection (Connor et al., 1997; Keele et al., 2008). 
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R5 are also found to be dominant in the transmission between individuals (Keele 
et al., 2008). However, in patients with disease progression, the virus expands its 
coreceptor use to include CXCR4, in addition to CCR5 (Connor et al., 1997; 
Schuitemaker et al., 1992). The primary difference between the sequences of R5 
and X4 viruses is within the V3 region of Env (Jensen et al., 2003). The 
mechanism of coreceptor switch during disease progression remains unclear 
though it has important consequences for therapy with HIV entry inhibitors.  
Coreceptor binding triggers the membrane fusion potential of Env. The 
last step of viral entry is membrane fusion mediated by gp41. The conformational 
changes induced by coreceptor binding expose the hydrophobic, glycine-rich 
fusion peptide region of gp41. The fusion peptide anchors into host cell 
membrane, and eventually forms a six-helical bundle (6HB) (Chan et al., 1997; 
Weissenhorn et al., 1997). Within the 6HB, three peripheral carboxy-terminal 
helices (HR2 domains) pack onto a central trimeric coiled-coil formed by heptad 
repeat 1 (HR1 domain) in an anti-parallel manner (Wilen et al., 2012) (Figure 
1.3). The conformational changes leading to HIV-1 entry are reminiscent of the 
low-pH-induced conformation of influenza hemagglutinin (Chan et al., 1997; 
Weissenhorn et al., 1997). Carboxy-terminal to the gp41 HR2 domain is the 
membrane-proximal external region (MPER) , which is accessible to the 
neutralizing antibodies 2F5 and 4E10 on the native Env trimer (Finnegan et al., 
2002; de Rosny et al., 2004). In contrast to the exposure of HR1 and HR2 upon 
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interaction with receptor and coreceptor, the MPER loses the accessibility as 
fusion progresses (Pancera et al., 2017).  
Membrane fusion mediated by viral proteins follows the general model for 
lipid bilayer fusion (Chernomordik et al., 1987; Melikyan, 2008). The outer 
monolayers of two membranes first join and initiate the fusion. The distal 
monolayers follow to come into direct contact and form a hemifusion diaphragm. 
Dilation of fusion pores to allow viral nucleocapsid delivery (~50 nm) is critical for 
effective infection, though the mechanism of pore enlargement is not clear. The 
expansion of viral pores to a size sufficient for viral entry are less favored than 
hemifusion or pore formation due to the higher energy cost (Melikyan, 2008). 
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Figure 1.3. Steps of HIV-1 entry.  
The transmembrane, gp41, and surface, gp120, subunits (1) of HIV-1 Env 
mediate viral entry. The binding of Env to CD4 causes the exposure of V3 loop 
(2), which mediates the co-receptor binding (3). Fusion peptides anchor 
themselves to the target membrane via their hydrophobic segments and forms 
six-helix bundle. It brings the viral and cellular membranes together and forces 
membrane to merge (4).  
Reprinted and adapted with permission from Cold Spring Harbor Laboratory 
Press (Wilen et al., 2012). 
 
 
 
 
 
 
Entry inhibitors. 
There are two major classes of entry inhibitors targeting either fusion or 
co-receptor binding. The HR1 and HR2 domains in gp41 have to interact with 
each other for conformational changes that ultimately drive membrane fusion. 
Synthetic peptides that mimic HR2 competitively inhibit the packing of HR2 
against HR1, and thus the formation of the 6HB. T-20 (enfuvirtide) was designed 
with this rationale, and shows potent antiviral activity in vivo (Kilby et al., 1998; 
Lalezari et al., 2003). CCR5 antagonists bind to a cavity within CCR5, thus 
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inhibiting membrane fusion by blocking the interaction between gp120 and CCR5 
(Dragic et al., 2000; Tsamis et al., 2003). The CCR5 antagonist Maraviroc was 
approved by the FDA for clinical use. It prevents the binding of CCR5 to the V3 
loop of gp120 (Dragic et al., 2000).  
  
Reverse transcription 
 Following the delivery of the viral capsid into the cytoplasm of the host 
cell, the single-stranded viral RNA genome needs to be converted into linear 
double-stranded DNA for the integration process. Reverse transcription and 
integration are the hallmarks of retroviruses. Howard Temin and David Baltimore 
first discovered reverse transcriptase (RT) from RNA sarcoma viruses, which 
synthesizes DNA from an RNA template (Baltimore, 1970; Temin and Mizutani, 
1970). An arsenal of FDA-approved antiretroviral drugs target HIV-1 RT. 
 
The molecular mechanism of reverse transcription 
 Two enzymatic activities in RT that carry out reverse transcription are a 
DNA polymerase that copies either an RNA or DNA template and an RNase H 
that degrades RNA in a duplex of RNA-DNA. A host tRNA initiates the synthesis 
of the first minus-strand DNA from the primer binding site (pbs) towards the 5’ 
end of viral RNA. DNA synthesis forms an RNA-DNA duplex, which is a substrate 
for RNase H. Subsequently, RNase H digests the 5’ end of the viral RNA and 
leaves the newly-synthesized minus-strand DNA. The ends of the viral RNA are 
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repeat sequences, R. They allow the newly-synthesized DNA to be transferred 
from the 5’ end to 3’ end, which results in the synthesis of the full-length genome. 
A polypurine tract (ppt) is the only region resistant to RNase H cleavage, and 
acts as the primer for the initiation of the plus-strand DNA.  
HIV-1 genomic RNAs are often nicked. The second copy of viral RNA 
allows the synthesis of minus-strand DNA to transfer to the second RNA 
template and bypass the nick. The template switching accounts for 
recombination happening during reverse transcription. Both ends of the DNA 
product formed during this process contains U3-R-U5, which comprise the LTRs 
at the ends of the provirus. In infected cells, DNA synthesis occurs in a reverse 
transcription complex (RTC), which consists of multiple viral proteins (Fassati 
and Goff, 2001).  
 
Genetic events during reverse transcription 
 The diversity of viruses within an infected individual suggests large genetic 
variation in patients (Keele et al., 2008). The high rate of virus turnover in 
infected individuals, in addition to a high mutation rate, drives the development of 
genetic variation (Coffin, 1995; Ho et al., 1995). The high frequency of mutations 
in part results from an error-prone RT lacking a proofreading mechanism, though 
there is no good way to exclude the contribution from host RNA polymerase II 
(Hu and Hughes, 2012). The total mutation rate for HIV-1 replication is 
approximately 2 X 10-5 per nucleotide per replication cycle, a rate that is close to 
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other retroviruses (Abram et al., 2010; Pathak and Temin, 1990). In addition to 
RT and RNA polymerase II, the host restriction factor APOBEC3G affects the 
fidelity and efficiency of reverse transcription by altering the synthesized minus-
strand DNA (Harris et al., 2003; Mangeat et al., 2003). This will be discussed 
later in this chapter.   
 Another genetic event happening during reverse transcription is 
recombination. Frequent HIV-1 recombination raises genetic diversity in the viral 
population and contributes to high-level multiple-drug resistance (Moutouh et al., 
1996). Recombination under immune selection pressure is a strategy of viral 
escape (Streeck et al., 2008). Template switching during the synthesis of minus-
strand DNA can generate a recombinant genetically distinct from the parental 
viral genomes. Such recombination requires two heterogenous RNA templates 
packaged into the same virion (Hu and Temin, 1990). The original model for 
template switching is that a break in one RNA template causes a switch to the 
other RNA copy (Coffin, 1979). A recently modified model suggests that the 
steady state between the rates of polymerization and RNA degradation 
determines in vivo template switching (Hwang et al., 2001). 
 
RT Inhibitors 
RT is the target for two distinct classes of antiretroviral agents: the NRTIs, 
which are analogs of native nucleoside substrates, and the NNRTIs, which 
bind in a site near the polymerase catalytic domain of RT (Kohlstaedt et al., 
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1992). NRTIs lacking 3’-OH moieties prevent the formation of 3’-5’ 
phosphodiester bonds between the elongating DNA chain and incoming 5’-
nucleoside triphosphates (Mitsuya et al., 1985; Richman, 2001). Currently, there 
are eight FDA-approved NRTIs: abacavir (ABC), didanosine (ddI), emtricitabine 
(FTC), lamivudine (3TC), stavudine (d4T), zalcitabine (ddC), zidovudine 
(AZT), Tenofovir disoprovil fumarate (TDF) (Arts and Hazuda, 2012). The binding 
of NNRTIs changes the conformation of the substrate-binding site and reduces 
the enzymatic activity of RT (Kohlstaedt et al., 1992). Four approved NNRTIs are 
etravirine, delavirdine, efavirenz, and nevirapine. Figure 1.4 summarizes the 
mechanisms of actions of NRTIs and NNRTIs.  
 Administration of the above drugs causes the emergence of drug-resistant 
viruses. Two mechanisms mediate resistance to NRTIs. One is caused by ATP-
dependent pyrophosphorolysis, which reverses chain termination via removal of 
NRTIs from the 3’ end of the nascent chain (Boyer et al., 2001). The other 
mechanism of NRTI resistance is the failure of NRTI incorporation into the 
nascent chain caused by mutations in RT (Garcia-Lerma et al., 2003; Margot et 
al., 2002; Quan et al., 1996).  NNRTI resistance is due to mutations in the 
NNRTI-binding pocket of RT (Arts and Hazuda, 2012).   
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Figure 1.4. Mechanisms of actions of NRTIs and NNRTIs. 
A. NRTIs incorporate themselves into newly synthesized DNA nucleoside chain, 
and stop attachment of nascent nucleosides and thus blocking ongoing viral DNA 
synthesis.  
B. NNRTIs bind to and alter the configuration of RT, thus affecting its enzymatic 
activity.  
Reprinted and adapted with permission from Springer Nature (Richman, 2001). 
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DNA integration 
 Integration of a DNA copy of the viral genome into host cell DNA is 
another hallmark of retroviruses. Once integration is completed, the proviral DNA 
is replicated during cycles of cell division. The provirus provides the template for 
transcription of viral RNA genomes and viral mRNAs for producing the viral 
proteins. The mechanism and biochemistry of integration have been extensively 
studied are well understood, which contributed to the identification of IN 
inhibitors. The first IN inhibitor received FDA approval in 2007 (Sato et al., 2006). 
Identification of the integration sites provides a footprint to trace the expansion of 
infected cells during viral persistence (Maldarelli, 2016) and attracts attention for 
efforts towards a cure (Lusic and Siliciano, 2017).   
 
The mechanism of integration 
 The DNA copy produced by reverse transcription together with several 
viral proteins form the preintegration complex (PIC) (Bowerman et al., 1989). The 
DNA breakage and joining steps of integration (Fujiwara and Mizuuchi, 1988) are 
illustrated in Figure 1.5. First, two nucleotides at the 3’ ends of each linear viral 
DNA need to be removed from the blunt ends (Figure 1.5A, B). These recessed 
3’ ends attack target DNA and generate a 5’ overhang of target DNA. The 5’ 
ends of this target DNA are joined to the 3’ends of the donor DNA to form the 
integration intermediate (Figure 1.5C). The distance of the sites of attack on the 
two target DNA strands is five nucleotides. The single-stranded gap and the 5’ 
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end overhang of viral DNA are repaired by cellular enzymes (Figure 1.5D, E), 
which forms the short duplication of target DNA sequences that flank integrated 
proviruses. 
 The mechanism of nuclear localization during integration has not been 
fully addressed. Several genome-wide siRNA analysis carried out in the efforts to 
discover host factors required for HIV-1 replication identified cellular proteins 
required for integration step (Brass et al., 2008; König et al., 2008). Among them, 
nuclear pore proteins transportin 3 and Nup358 have been shown to be required 
for nuclear translocation and integration. After the PIC enters the nucleus, it is 
also possible that the ends of the viral DNA are ligated to each other and form 2-
LTR circles.   
IN binds to host lens epithelium-derived growth factor (LEDGF/p75) and 
catalyzes HIV DNA integration (Llano et al., 2006). Before the essential role of 
LEDGF/p75 in integration was established, it was well known that IN is tethered 
to chromatin by LEDGF/p75 (Cherepanov et al., 2003; Llano et al., 2004). The 
functional modules for the tethering mediated by LEDGF/p75 are the amino-
terminal PWWP, A/T-hook elements binding to chromatin, and a carboxy-
terminal integrase-binding domain (Cherepanov et al., 2004). However, changes 
in overall levels of HIV integration and replication in LEDGF/p75-knockdown cells 
have been modest (Ciuffi et al., 2005; Llano et al., 2004). The reason is 
that fractionally minute levels of endogenous LEDGF/p75 are sufficient for 
integration (Llano et al., 2006). Binding sites on chromosomes for LEDGF/p75 lie 
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preferentially in active transcription units, which are in agreement with HIV-1 
integration sites. The interaction site for LEDGF/p75 with integrase is a promising 
target for antiretroviral therapy (Christ et al., 2010). 
 
 
 
 
Figure 1.5. DNA cutting and joining steps of integration.  
A. The linear viral DNA copies with blunt ends.  
B. 3’ end processing by removing two nucleotides from 3’ end of each viral DNA 
copy.  
C. DNA-strand transfer. The processed 3’ ends of viral DNA are joined to the 5’ 
ends of the target DNA. Steps B and C are catalyzed by IN.  
D. Cellular enzymes removes the 5’ overhang of viral DNA and fill the gap 
between viral and target DNA. Steps C and D are referred as strand transfer.  
E. The integrated provirus.  
Reprinted and adapted with permission from Cold Spring Harbor Laboratory 
Press (Wilen et al., 2012).  
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Integration site 
 Integration site selection by retroviruses has been of great interests 
because of its significance for gene therapy. Recently, this field has attracted 
more attention since the integration profile of HIV-1 is useful to characterize 
latently infected cells (Lusic and Siliciano, 2017; Siliciano and Greene, 2011). 
The analysis of the DNA sequences at junctions between proviral DNA and host 
DNA shows that integration occurs within actively transcribed host genes in 
resting CD4 T cells of infected individuals (Han et al., 2004). Active transcription 
units are characterized by high G/C content, high CpG island density, high 
frequencies of Alu repeats, and low frequencies of LINE repeats. Open chromatin 
is not the sole reason accountable for targeting active transcription units, since 
other retroviruses favor different target sites in chromosomes (Wu et al., 2003). 
IN is the principal viral determinant of target site preference (Lewinski et al., 
2006).  
  Analysis of HIV proviruses in CD4+ lymphocytes from individuals after 
prolonged combination ART reveals that 40% of the integrations are in clonally 
expanded cells and proviruses are integrated into genes associated with 
regulation of cell growth (Maldarelli et al., 2014). Another group using a 
modified translocation-capture sequencing method identified hot spots for 
integration near human Alu sequences (Cohn et al., 2015). With the development 
of long-read sequencing technologies such as Pacific Biosciences sequencing, it 
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is possible to directly examine longer sequences of HIV with the junction 
sequence and host genome sequence in a high-throughput fashion.  
 
Integrase inhibitors 
IN is the most recent target for antiretroviral drug development (Hazuda et 
al., 2004). All integrase inhibitors in development target the joining of viral and 
cellular DNAs. The mechanism of action of IN inhibitors involves binding to the 
complex between IN and the viral DNA, as well as interactions with the cofactor 
Mg2+ in the active site of IN (Grobler et al., 2002). Mutations at the IN active site 
that coordinate the essential cofactor Mg2+ can cause the resistance to IN 
inhibitors.  
 
Viral gene expression. 
 After being integrated into the host genome, the HIV-1 provirus serves as 
the template for transcription. HIV-1 gene expression is orchestrated by two viral 
regulatory proteins, Tat and Rev. Tat activates viral transcription by stimulating 
elongation from the 5’ LTR. Rev transports mRNAs encoding the structural viral 
proteins from the nucleus to the cytoplasm.  
 
Regulation by Tat 
 The HIV-1 5’ LTR acts as a promoter and enhancer. Tat was first 
discovered as a transacting factor required for viral gene expression under the 
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control of the viral LTR (Sodroski et al., 1985). Tat functions through the 
transactivation-responsive region (TAR), a regulatory element located 
downstream of the initiation site. The specific stem-loop secondary structure of 
TAR is required for its biological activity (Berkhout et al., 1989). Tat recognizes 
TAR via a U-rich region at the loop of TAR and initiates the conformational 
changes of TAR RNA (Feng and Holland, 1988).  
 Positive transcription elongation factor b (P-TEFb) is a cofactor essential 
for Tat-mediated transactivation. P-TEFb was identified by Tat-affinity 
chromatography and consists of cyclin T1 and cyclin-dependent kinase 9 (CDK9) 
(Wei et al., 1998; Zhu et al., 1997). Tat requires some transcription before HIV 
gene expression is initiated. Thus, Tat regulates the elongation of all viral 
transcripts that contain TAR, rather than initiating the transcription (Kao et al., 
1987). The binding of Tat to P-TEFb activates CDK9. The regulation of P-TEFb 
itself is critical for HIV transcription. The majority of P-TEFb is sequestered and 
inactive in a 7SK small nuclear ribonucleoprotein (7SK snRNP) complex. 7SK 
snRNP inhibits the kinase activity of CDK9 and prevents recruitment of P-TEFb 
to the HIV-1 promoter (Nguyen et al., 2001; Yang et al., 2001). Tat overcomes 
this sequestration by disrupting 7SK snRNP complexes, and induces the release 
of free P-TEFb.  
 
The LTR  
 24 
The U3 region at the 5’ end of the HIV-1 LTR contains binding sites for 
transcription factors including nuclear factor of activated T cells (NFAT), NF-kB 
and specificity protein 1 (SP1) (Kinoshita et al., 1998; Nabel and Baltimore, 
1987). The “enhancer region” contains two NF-kB binding motifs.  
HIV-1 integration favors active transcription units. Thus, integrated 
proviruses in actively transcribed genes can be silenced by heterochromatin 
(Cary et al., 2016). A well-known mechanism of maintaining latency is the 
recruitment of histone deacetylases (HDACs) to the HIV-1 5’ LTR, forming a 
repressive chromatin environment (Margolis et al., 2016). Given that proviral 
latency is the principal barrier to a cure, reactivation of latent resting CD4+ T cells 
is the current strategy to clear the viral reservoir. Latency reversing agents 
(LRAs) are tools to be studied and further developed for this purpose (Margolis et 
al., 2016). So far, the most widely investigated LRAs are histone deacetylase 
inhibitors (HDACis). Though direct proof-of-concept of HDACi has been achieved 
in clinical studies, the potency and effectiveness of these inhibitors need further 
improvement (Archin et al., 2012).  
 
Rev 
 HIV-1 primary transcripts undergo extensive alternative splicing to 
produce all the mRNAs to encode viral proteins. In addition to generating full-
length gag, gag-pol, and env, HIV-1 produces a complex pattern of spliced RNAs 
to encode the essential regulatory genes and accessory genes. Unspliced and 
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incompletely spliced transcripts from cellular genes are degraded in the cellular 
environments. To survive in the host, the viral accessory protein Rev promotes 
the transportation of such viral RNAs out of the nucleus. Rev binds to viral RNAs 
that contain the Rev-responsive element (RRE), located in the env gene (Malim 
et al., 1989; Sodroski et al., 1986).  
 The expression of viral proteins in either the early or late phases of the 
HIV-1 life cycle is determined by the level of Rev (Figure 1.6) (reviewed in Karn 
and Stoltzfus, 2012). Full-length unspliced ~9-kb, incompletely spliced ~4-kb 
mRNA and completely spliced ~1.8-kb mRNAs are produced at both early and 
late times. At the early phase of HIV-1 mRNA expression, there is no Rev or only 
a low-level of Rev. Unspliced or incompletely spliced mRNAs fail to be 
transported out of the nucleus and are either spliced or degraded by cellular 
enzymes (Figure 1.6A). When the level of Rev in the nucleus exceeds the 
threshold necessary for function, all viral mRNAs are transported to the 
cytoplasm and translated (Figure 1.6B). 
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Figure 1.6. Early and late phases of HIV-1 mRNA expression.  
A. In the absence of Rev or with low-level Rev, only Rev, Tat, and Nef are 
expressed.  
B. When Rev accumulates, unspliced and incompletely spliced mRNAs are 
transported out of the nucleus. 
Reprinted and adapted with permission from Annual Reviews, Inc (Karn and 
Stoltzfus, 2012; Pollard and Malim, 1998).  
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Viral particle production 
 The last step of the HIV-1 life cycle is assembly and budding. Before the 
progeny virions become infectious and can infect the next target cell, they 
undergo maturation. The Gag glycoprotein and its proteolytic products drive the 
process. There are three stages based on virion morphogenesis: assembly, 
budding, and maturation.  
 
Assembly 
 HIV-1 particle production occurs in a series of steps promoted by the viral 
Gag protein (Ono and Freed, 2001). Gag domains are separated by PR cleavage 
sites (Figure 1.7A). MA is the amino-terminal domain of Gag. It binds to the 
plasma membrane and recruits the Env protein. Genetic and biochemical 
evidence suggested the direct interaction of the HIV-1 gp41 cytoplasmic tail with 
MA, which is required for HIV-1 maturation (Murakami and Freed, 2000; Wyma et 
al., 2000). The central domain of Gag, CA, mediates protein-protein interactions 
during assembly and forms the conical core of mature virions. The NC domain 
functions to capture the viral genome during assembly. P6 at the carboxy-
terminal contains late assembly domains, which bind to the cellular ESCRT 
membrane fission machinery to promote viral budding from the plasma 
membrane. The p6 domain also contains binding sites for the HIV-1 accessory 
protein Vpr. 
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 The viral membrane is derived from the cellular plasma membrane. 
However, viral lipid composition differs from that of the producer cell (Ono, 
2009). The HIV Gag and Gag-Pro-Pol polyproteins specifically associate with 
cholesterol-enriched, detergent-resistant microdomains (“rafts”) at the plasma 
membrane (Ono and Freed, 2001). Mass spectrometry provided a quantitative 
analysis of the lipid constituents of HIV and of the difference from the host 
membrane (Brugger et al., 2006). 
 The dimer initiation site (DIS) in the 5’ UTR of the genomic viral RNA 
mediates the dimerization of two copies of the RNA genome. RNA dimerization is 
required for RNA packaging. RNA-Gag interactions facilitate the aligning of Gag 
molecules at the plasma membrane (Kutluay and Bieniasz, 2010). The carboxy-
terminal domain of CA stabilizes the interactions of RNA and Gag. The packing 
signal (Y site) at the 5’ UTR comprises four stem loops. The splice donor site 
within the Y site contributes to the selection of unspliced RNA for efficient 
packaging. In addition to the viral genome RNA, virions also package tRNA 
primers required for the initiation of reverse transcription.   
The application of imaging technologies and structural analyses further 
advanced our understanding of HIV-1 assembly and budding. Total-internal-
reflection fluorescent microscopy in living cells allows the study of the genesis of 
individual virions in real time (Ivanchenko et al., 2009; Jouvenet et al., 2008). The 
accumulation of Gag protein in cells accelerates the membrane assembly rate of 
virions. The average time for assembly is 5-6 min. Cryo-electron tomography 
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(cryo-EM) of budding viruses showed that the immature Gag lattice is established 
as the virus assembles (Carlson et al., 2010). High-resolution cryo-EM allowed 
the positioning of individual protein domains and defined the three-dimensional 
structure of the immature Gag lattice in greater detail (Briggs et al., 2009; Schur 
et al., 2015).  
 
Budding 
 To facilitate the release of virions from the plasma membrane, retroviruses 
usurp the host ESCRT (endosomal sorting complexes required for transport) 
machinery, which normally creates vesicles that bud into late endosomal 
compartments called multivesicular bodies (MVB), and also separates two 
daughter cells during cytokinesis (Bieniasz, 2009; Morita and Sundquist, 2004). 
Two late assembly domains in p6 recruit early-acting ESCRT factors. First, PTAP 
motif in p6 binds to the ubiquitin E2 variant (UEV) domain of tumor susceptibility 
gene 101 (Tsg101) (Garrus et al., 2001; Martin-Serrano et al., 2001). Tsg101 is a 
subunit of the ESCRT-I complex. The second late domain in p6 is a YPXL motif 
which binds the ESCRT factor ALIX (Strack et al., 2003). Tsg101 and ALIX both 
function by recruiting ESCRT-III and VPS4 complexes, which in turn mediate 
membrane fission (Bieniasz, 2009; Morita and Sundquist, 2004). Tetherin is a 
host restriction factor that can block a later step of HIV-1 release, which will be 
discussed in detail below.  
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Maturation 
 Upon budding from producer cells, HIV-1 progeny virions are in an non-
infectious, immature form. The Gag polyprotein first assembles into spherical 
immature particles and radially points toward the virion interior (Figure 1.7 B, C 
left). Upon the PR-mediated cleavages of the Gag and Gag-pol polyproteins, the 
immature virions transits into its mature infectious form, resulting in the conical 
core of the infectious virus (Figure 1.7 B, C right) (Gross et al., 2000). Gag 
processing also affects Env-mediated fusion (Murakami et al., 2004). 
Unprocessed Gag interacts with the gp41 cytoplasmic tail, and suppresses Env-
mediated viral fusion (Murakami et al., 2004). The conical core of viral particles is 
composed of ~1200 copies of CA, while MA remains associated with the inner 
side of the viral membrane (Briggs et al., 2003). Intersubunit CA interactions 
stabilized the capsid lattice. 
 The viral capsid is crucial for host-viral interactions during the early stages 
of HIV-1 replication. It interacts with TRIM5a and cyclophilin A (Keckesova et al., 
2006; Stremlau et al., 2006). The stabilization of the capsid matters for reverse 
transcription (Forshey et al., 2002). Mutational analyses of CA suggests that the 
capsid plays an important role in nuclear import of the PIC (Lee et al., 2010; 
Yamashita et al., 2007).  
 HIV-1 PR cleaves the viral Gag and Gag-pol polyprotein precursors during 
maturation, and it is an effective drug target. Ten PR inhibitors are currently 
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approved by FDA. However, ~ 20 substitutions are known to be associated with 
resistance to PR inhibitors (Shafer et al., 2001).  
 
 
 
Figure 1.7. The Gag polyprotein coordinates assembly, budding and 
maturation. 
A. Domain composition of the HIV-1 Gag protein. Arrows denote the five sites 
that are cleaved by the viral PR during maturation.  
B. Schematic model showing the organization of the immature (left) and mature 
(right) HIV-1 virion. 
C. Central section from a cryo-EM tomographic reconstruction of an immature 
(left) and mature (right) HIV-1 virion. 
Reprinted and adapted with permission from Cold Spring Harbor Laboratory 
Press (Sundquist and Krausslich, 2012).  
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Cell-to-cell transmission 
 
 It was first reported in 1992 that dendritic cells can transfer infectious HIV-
1 to uninfected CD4+ T cells without themselves becoming infected, so called 
trans-infection (Cameron et al., 1992). The HIV receptors CD4, CCR5, and 
CXCR4 on the T cell are recruited to the dendritic cell/T cell interface while the 
viruses are concentrated in the same region (McDonald et al., 2003). However, 
the mechanism of trans-infection and its importance in vivo within distinct 
anatomical compartments is not clear. A recent study of murine leukemia virus 
(MLV) infection in mice shows that robust infection of MLV in lymph nodes and 
spleen requires CD169-dependent trans-infection (Sewald et al., 2015).  
In T-lymphocyte cultures, the effective cell-cell transmission of HIV-1 is via 
the virological synapse (VS) (reviewed in Alvarez et al., 2014). HIV-1 release is 
polarized and accumulated at the cell-to-cell contact (Haller et al., 
2014). Polarization and formation of VS are dependent on an intact microtubule 
and actin cytoskeleton (Jolly et al., 2007). The cellular adhesion molecules 
ICAM-1 and LFA-1 are suggested to stabilize VS (Jolly et al., 2007). Recent 
study provided evidence for existence of in vivo VS using three-dimensional 
electron tomography (Ladinsky et al., 2014). Although cell-to-cell transmission 
and cell-free transmission exhibit vastly different efficiencies, they seem to 
involve fundamentally similar molecular mechanisms of viral assembly, budding 
and release (Sundquist and Krausslich, 2012).  
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HIV-1 pathogenesis 
 
 The in vivo replication of HIV-1 viruses causes the loss of CD4+ T cells. In 
the absence of ART, HIV-1 infection leads to AIDS, characterized by numerous 
opportunistic infections and symptoms like dementia and wasting. Figure 1.8 
shows the typical disease progression marked by the reduction of CD4+ T cells 
and viral loads in infected individuals without treatment (Coffin and Swanstrom, 
2013).  
 During the first 1-2 weeks, the transmitted virus, now suggested to be a 
single virion (Keele et al., 2008), starts to replicate and spread from the initial 
infection site. Neither viremia nor immune responses are detectable. From 2-4 
weeks, a high level of viremia (up to 107 or more copies of viral RNA per milliliter 
of blood) develops, accompanied by “flu-like” symptoms. At the peak of viremia, 
antibodies are produced and cytotoxic T lymphocyte (CTL) responses take place. 
A recent study of acutely infected patients suggests that anti-HIV-1 specific CTL 
responses during hyperacute infection impact the viral set point (Ndhlovu et al., 
2015). High-level viremia is due to the absence of an early immune response and 
a large number of activated CD4+ T cells, which are the target cells for HIV-1 
replication. The end of this phase is characterized by the drop in the level of 
viremia, and a transient drop in the number of CD4+ T cells. The following 1 to 20 
years is clinical latency. The HIV-1 viral set point refers to the stable or slowly 
increasing level of viral load during this phase. The number of CD4+ T is near 
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normal or gradually falling. Plasma viral load is a better predictor of progression 
to AIDS than the number of CD4+ T cells (Mellors et al., 1996). Finally, the 
clinical hallmark of AIDS is that the number of CD4+ T cells drops below 200 
cells/µL). Opportunistic infections start to appear.  
 ART has changed the fate of HIV-1-infected individuals. The majority of 
patients on suppressive therapy have low levels of viremia. However, once ART 
is interrupted, viral rebound occurs. The reason is that HIV-1 can establish a 
state of latent infection at the level of individual T cells (Siliciano and Greene, 
2011). Activated CD4+ T cells are highly susceptible to HIV-1 infection and 
subject to rapid turnover (Ho et al., 1995). However, some activated CD4+ T cells 
may become infected and then survive long enough to revert back to a resting 
state (Finzi et al., 1999). Latent virus persists even in patients on potent 
antiretroviral therapy since it resides in long-lived memory T cells (Finzi et al., 
1997). This latent reservoir is now the major barrier to the cure of HIV-1 infection. 
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Figure 1.8. Time course of typical HIV-1 infection.  
Patterns of CD4+ T cell decline and viremia vary greatly from one patient to 
another. 
Reprinted and adapted with permission from Cold Spring Harbor Laboratory 
Press (Coffin and Swanstrom, 2013).  
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HIV restriction factors 
 
 In addition to conventional innate and adaptive immune responses, 
humans and other mammals have evolved specific antiviral factors. These host-
encoded restriction factors serve as effective inhibitors of retroviral replication. 
Some of the restriction factors are constitutively expressed, while some of them 
are induced by interferons as part of the innate immune response. Their 
advantage is that they do not have to ‘‘learn’’ to combat viruses but are already 
active at the first virus-cell interaction (reviewed in Kirchhoff, 2010; Malim and 
Bieniasz, 2012). HIV-1 evades the defense of antiviral factors in human cells, 
thus allowing efficient viral replication. In contrast, the ability of HIV-1 to replicate 
in nonhuman cells is often severely compromised by restriction factors (Malim 
and Emerman, 2008). Thus, restriction factors are important determinants of viral 
host range and cross-species transmission (Gaddis et al., 2004; Keckesova et 
al., 2006).  
This chapter discusses three well-defined restriction factors that potently 
inhibit HIV-1: namely, APOBEC3G (apolipoprotein B mRNA-editing enzyme, 
catalytic polypeptide-like 3G), TRIM5a (tripartite motif 5-a), and tetherin (BST-2 
or CD317). This introduction focuses on the mechanisms by which they inhibit 
viral replication, how HIV-1 evades their protection, and their potential 
contributions to viral pathogenesis and cross-species transmission.  
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Discovery of HIV-1 restriction factors 
 Studies of ecotropic MLV initiated the field of “restriction factor.” The 
isoforms of mouse-encoded gene Fv1, Fv1n and Fv1b, determines the tropism 
of MLV (Best et al., 1996). Mice carrying Fv1n are susceptible to N-tropic MLVs, 
but resistant to B-tropic MLVs (Best et al., 1996).  
 Although the approaches for discovering restriction factors have evolved 
over the decades as novel technologies emerge, the general strategy remains 
the same. The potent restriction factor APOBEC3G, which is counteracted by 
HIV-1 Vif, was identified by comparing cDNAs from the cell lines that are either 
permissive or nonpermissive for Vif-deficient viruses (Sheehy et al., 2002). An 
analysis of differential expression via microarray among cell lines with distinct 
phenotypes induced by type I interferon revealed the role of tetherin in the 
inhibition of HIV-1 virion release in the absence of Vpu (Neil et al., 2008). 
TRIM5a, which targets incoming HIV-1 capsids, was discovered by exploiting the 
transfer of resistance to HIV-1 between permissive and nonpermissive cells. 
Isolation of a cDNA conferring resistance uncovered the restriction factor 
TRIM5a (Stremlau et al., 2004).  
 
APOBEC3G 
APOBEC3G is a cytidine deaminase, which mediates the editing of 
cytidine residues to uridines. In the absence of Vif, APOBEC3G exerts its 
inhibitory activity by being selectively packaged into HIV-1 particles by binding to 
 38 
the NC domain of Gag (Bogerd and Cullen, 2008; Zennou et al., 2004). After 
being transferred into target cells, APOBEC3G catalyzes the deamination of 
cytidine to uridine in nascent single-stranded negative-strand cDNA (Harris et al., 
2003), and causes lethal guanosine-to-adenosine hypermutation within the viral 
plus-strand (Mangeat et al., 2003; Zhang et al., 2003). In addition, APOBEC3G 
inhibits viral DNA synthesis during reverse transcription (Bishop et al., 2008; 
Miyagi et al., 2007).  
 The antiretroviral activity of APOBEC3G is antagonized by the HIV-1 
accessory protein Vif. Vif serves as an adaptor protein to recruit APOBEC3G 
to ubiquitin ligase complexes, resulting in polyubiquitination and proteasomal 
degradation of APOBEC3G, thereby preventing its packaging into progeny 
virions (Marin et al., 2003; Sheehy et al., 2002; Stopak et al., 2003; Yu et al., 
2003). In addition to Vif-mediated regulation, type I interferon can induce 
APOBEC3G proteins (Koning et al., 2009). The contribution of APOBEC3G-
mediated hypermutation to the HIV-1 landscape is not clear (reviewed in Hu and 
Hughes, 2012). The mechanism of APOBEC3G-mediated restriction and its 
counteraction by Vif is summarized in Figure 1.9. A small molecule RN-18, that 
antagonizes Vif and functions only in the presence of APOBEC3G, is under 
development (Nathans et al., 2008). 
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TRIM5a 
 TRIM5a was initially identified as the factor responsible for the resistance 
of rhesus macaque cells to HIV-1 infection (Stremlau et al., 2004). Subsequent 
studies revealed that TRIM5a from a variety of primates possess similar 
antiretroviral activities (Hatziioannou et al., 2004; Keckesova et al., 2004; Perron 
et al., 2004; Yap et al., 2004). TRIM5a proteins are poor inhibitors of retroviruses 
derived from the same host species, but effectively restrict retroviruses from 
other species. TRIM5a is a ~500 amino acid cytoplasmic protein characterized 
by the TRIM (tripartite) motif, which is composed of RING, B-box 2, and coiled-
coil domains. A SPRY domain at the carboxy-terminus governs the species-
specific restriction by each TRIM5a protein. An analysis of the evolutionary 
history of TRIM5a revealed positive selection within the SPRY domain (Sawyer 
et al., 2005; Song et al., 2005). The SPRY domain also governs the binding of 
TRIM5a to HIV-1 capsid (Stremlau et al., 2006).  
 The mechanism by which TRIM5a blocks HIV-1 infection is not fully 
understood (Figure 1.9). Studies suggest that TRIM5a can specifically recognize 
the capsid and promote its rapid disassembly (Stremlau et al., 2006). Higher-
order TRIM5a oligomerization contributes to the efficiency of capsid recognition, 
and thus promotes antiviral potency (Diaz-Griffero et al., 2009). A very recent 
study suggests that in addition to providing a cross-species barrier, human 
TRIM5a is a cell-specific restriction factor dependent on C-type lectin receptor 
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function (Ribeiro et al., 2016). It potently restricts HIV-1 infection of Langerhans 
cells but not that of subepithelial DC-SIGN+ dendritic cells. 
 
Tetherin 
 Vpu is required for efficient HIV-1 particle release in certain human cells, 
while it is dispensable in some other human cells. The requirement for Vpu 
during virion release is inducible by IFN-a treatment (Neil et al., 2007). A 
comparison of the genetic profiles of cells with distinct requirements for Vpu for 
virion release identified tetherin as the restriction factor counteracted by Vpu 
(Van Damme et al., 2008; Neil et al., 2008).  
 In the absence of Vpu, tetherin traps the budding virions at the surface of 
infected cells, and their accumulation causes nascent virion endocytosis (Neil et 
al., 2006). Tetherin is a type II single-pass transmembrane protein with a 
transmembrane anchor at the amino-terminus and a glycophosphatidylinositol 
lipid anchor at its carboxyl-terminus. These membrane anchors are linked by an 
extracellular domain with a coiled-coil structure (Hinz et al., 2010; Yang et al., 
2010). Mutational analyses suggest that the configuration of tetherin rather than 
its primary sequence is required for antiviral activity (Perez-Caballero et al., 
2009). Both of the anchor domains are essential for tethering function (Perez-
Caballero et al., 2009). One model of tetherin action proposes that one 
transmembrane anchor is inserted into the cell membrane and the other into the 
virion envelope (Figure 1.9).   
 41 
 HIVs and SIVs have independently evolved antiviral tools to antagonize 
tetherin. HIV-1 Vpu colocalizes with and binds to tetherin, and reduces the level 
of tetherin at the cell surface (Van Damme et al., 2008; Neil et al., 2008). HIV-1 
Vpu antagonizes tetherin by causing its internalization or trapping it in a 
perinuclear compartment (Dubé et al., 2010; Mitchell et al., 2009). The precise 
mechanism is not yet entirely clear. In contrast, SIVs use Nef to antagonize 
tetherin (Jia et al., 2009; Zhang et al., 2009). Nef-binding proteins are not 
required for the antagonism of tetherin, and the mechanism by which Nef 
counteracts tetherin is not clear. SIV Envs were shown to antagonize tetherin as 
well (Gupta et al., 2009).  
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Figure 1.9. Interplay between restriction factors and accessory proteins. 
HIV-1 RNA is shown in light blue, HIV-1 cDNA in dark blue, and restriction 
factors in red. The sites of Vif, Vpu, and Nef antagonism are indicated.  
Reprinted and adapted with permission from Cold Spring Harbor Laboratory 
Press (Malim and Bieniasz, 2012). 
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Newly defined restriction factors 
 Though many restriction factors targeting distinct steps of the HIV-1 
replication cycle have been identified and well-characterized, perhaps more 
restriction factors remain to be discovered (Malim and Bieniasz, 2012). Rapidly 
evolving genetic approaches and high-throughput technologies make it possible 
to explore novel restriction factors on a larger scale. Park et al. used a genome-
wide CRISPR-based screen to identify host factors in a physiologically relevant 
cell system (Park et al., 2017). They repetitively infected a pool of knockout 
mutants with R5 viruses, followed by an analysis of surviving cells compared with 
parental cells. Among five factors they identified, four of them facilitated viral 
entry, while only one, activated leukocyte cell adhesion molecule (ALCAM), was 
required for cell-to-cell HIV transmission. No host factors involved in late stages 
of HIV-1 replication were identified, which is perhaps not surprising, since their 
approach tends to select for host factors required for early events in HIV-1 
replication.   
Starting with unexplained inhibitory effects of type I interferon on early 
steps of the HIV-1 replication cycle, two groups identified myxovirus resistance 2 
(MX2) as an interferon-inducible inhibitor of HIV-1 replication (Goujon et al., 
2013; Kane et al., 2013). A comparison of gene expression profiles in cell lines 
that differ in their ability to support the inhibitory action of interferon-a at early 
steps of the HIV-1 replication cycle resulted in the identification of MX2. The 
block to infection occurs at a late post-entry, preintegration step of HIV-1 
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replication. MX2 blocks HIV-1 by inhibiting CA-dependent nuclear import of 
subviral complexes (Goujon et al., 2013; Kane et al., 2013). 
 An unknown restriction factor imposes a quite formidable barrier to HIV-1 
infection in human dendritic and myeloid cells (Goujon et al., 2008; Hirsch et al., 
1998). Two groups identified SAMHD1 (SAM domain HD domain-containing 
protein 1) as the dendritic- and myeloid-cell specific restriction factor (Hrecka et 
al., 2011; Laguette et al., 2011). HIV-2/SIVsm accessory protein Vpx counteracts 
SAMHD1 by loading it onto an ubiquitin ligase, resulting in proteasome-
dependent degradation of the protein.  
 
  
The role of Nef in HIV-1 replication and pathogenesis 
 
The negative factor (Nef) of HIV-1 is a ~27 kDa myristoylated protein that 
resides both in the cytoplasm and in association with cytoplasmic membranes. 
Nef is abundantly expressed early during the viral life cycle. Though initially Nef 
was thought to be a negative factor that inhibits viral replication (Cheng-Mayer et 
al., 1989), subsequent studies on Nef demonstrated its key role in disease 
progression and pathogenesis. Individuals infected with Nef-deficient HIV-1 
maintained low viral loads and normal CD4 lymphocyte counts in the absence of 
antiretroviral treatment (Deacon et al., 1995; Kirchhoff et al., 1995). In rhesus 
monkeys infected with SIVmac, a functional Nef is required for maintaining high 
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virus loads and for full pathologic potential (Kestier et al., 1991). Rhesus 
monkeys vaccinated with live attenuated SIVmac with a deletion in nef are 
protected against live, pathogenic SIVmac (Daniel et al., 1992). However, 
subsequent studies have shown that the live attenuated SIV vaccine with 
deletions in nef can cause AIDS in infant and adult macaques (Baba et al., 1995, 
1999). Nef performs a striking number of activities by modulating signal 
transduction cascades and protein trafficking. Some key functions of Nef are 
summarized in Figure 1.11. 
 
Functional domains in Nef 
Nef consists of an array of potential protein-protein interaction domains 
(Geyer et al., 2001; Roeth and Collins, 2006). The structure fragments and 
functional domains were assembled into the full-length Nef polypeptide (Geyer 
and Peterlin, 2001). The Nef structure is partitioned into three segments: a 
myristoylated membrane anchoring region at the amino-terminus, followed by an 
a-helical core domain, and a carboxy-terminal flexible loop (Figure 1.10). An 
amino-terminal MGxxx(S/T) motif mediates the myristoylation of Nef. Several 
motifs are involved in signaling. For instance, a proline-rich (PxxP)3 sequence 
cluster interacts with SH3 domains of Src family kinases. It mediates the 
interactions between Nef and signaling proteins like Hck and Vav, which is 
required for cellular activation by Nef (Fackler et al., 1999). A di-arginine at 105, 
106 is required for the activation of p21-activated kinase (Pak) by Nef (Fackler et 
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al., 1999). Several motifs are reported to be involved in the downregulation of 
host proteins from the plasma membrane by Nef. An endocytic (E/D)xxxLL signal 
(dileucine motif) is best preserved. In addition, two aspartic acid residues (D174, 
D175) participate in the downregulation of CD4 (Aiken et al., 1994). Motifs 
involved in the Nef-mediated CD4 and MHC-I downregulation are located in 
flexible regions of Nef, suggesting the recognition of primary Nef sequences by 
endocytic machinery. In contrast, interaction sites for SH3 domains are located 
within the well-folded core domain, indicating the recognition of highly structured 
protein surfaces. 
In addition to HIV-1, HIV-2 and SIVs also encode Nef. Though several 
regions are highly conserved, there are many differences (Figure 1.11). The core 
domain of Nef is relatively conserved. The amino- and carboxy- termini 
containing extended loop sequence are less conserved. These sequences are 
enriched in motifs for cellular trafficking (Roeth and Collins, 2006).   
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Nef-mediated downregulation of surface proteins 
In HIV-1-infected T cells, Nef downregulates critical immune receptors on 
the cell surface including CD4, MHC-I, CD28, and CXCR4 (Bell et al., 1998; Guy 
et al., 1987; Haller et al., 2014; Kirchhoff, 2010; Schwartz et al., 1996). These 
receptors are recruited to the endocytic machinery or rerouted to lysosomes for 
degradation (Figure 1.11).  
Removing the antigen-presenting molecule MHC-I is one of the immune 
evasion strategies of HIV-1. Downregulation of MHC-I in HIV-1-infected CD4+ T 
cells was reported years before the mechanism was identified (Scheppler et al., 
1989). HIV-1 Nef prevents the exposure of viral antigens on the surface of HIV-
infected cells by reducing the surface expression of MHC-I (Schwartz et al., 
1996). This function allows HIV-infected cells to escape recognition and lysis by 
antiviral CTLs in primary T cell models (Collins et al., 1998). Interestingly, HIV-1 
selectively downregulates some allotypes of MHC-I while sparing others on the 
surface. Nef downregulates human leukocyte antigen (HLA)-A and HLA-B 
without reducing HLA-C and HLA-E surface levels, which would diminish 
inhibitory signals for NK cells (Cohen et al., 1999). In this way, Nef protects 
infected cells from both adaptive and innate immunity. A recent study 
demonstrated that Vpu in primary HIV isolates downregulates HLA-C, which 
leads to the downregulation of all major MHC-I molecules by HIV-1 (Apps et al., 
2016).  
Nef also down-regulates the viral receptor CD4. This activity is highly 
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conserved among SIV and HIV-1 Nefs (Aiken et al., 1994; Benson et al., 1993). 
The presence of CD4 on the surface of infected cells reduces the efficiency of 
virus budding and viral infectivity (Spina et al., 1994). Moreover, complex 
formation between CD4 and the HIV-1 Env glycoprotein disrupts the trafficking of 
both proteins (Roeth and Collins, 2006). The downregulation of CD4 by Nef also 
prevents viral superinfection (Aiken et al., 1994; Benson et al., 1993).  
Nef disrupts the trafficking of MHC-I and CD4. Nef has been shown to 
bind to the early forms of MHC-I molecules with unphosphorylated cytoplasmic 
tails, which are newly loaded with foreign peptides (Kasper et al., 2005). In the 
presence of Nef, MHC-I molecules accumulated in the trans-golgi network (TGN) 
(Roeth et al., 2004), where the clathrin adaptor protein complex 1 (AP-1) 
normally functions and binds to sorting signals in the cytoplasmic tails of proteins. 
Nef recruits AP-1 to reroute MHC-I from the TGN to lysosomes in infected T cells 
(Roeth and Collins, 2006). Nef also binds to the cytoplasmic tail of CD4 and 
recruits AP2 to transport CD4 from the cell surface to lysosomes for degradation 
(Cluet et al., 2005; Ross et al., 1999). 
A growing list of surface proteins is shown to be affected by Nef, including 
CD28, CXCR4, DC-SIGN, CD8, MHC-II and the invariant chain (Haller et al., 
2014; Schindler et al., 2003; Sol-Foulon et al., 2002; Stumptner-Cuvelette et al., 
2001; Swigut et al., 2001; Venzke et al., 2006). CD3 is only downregulated by 
HIV-2 and SIV Nefs. But this function is missing in HIV-1 and its simian 
precursors (Schindler et al., 2006). A complete understanding of the mechanism 
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and selectivity of Nef downregulation needs further investigation.  
 
Nef modulates signal transduction pathways 
 Nef interacts with various cellular kinases and modulates the responses of 
HV-1 infected T cells to TCR-mediated stimulation. Nef together with Lck is 
recruited to cell-cell contact interfaces after TCR stimulation (Fenard et al., 
2005). Nef promotes the induction of cellular transcription factors, such as NF-AT 
and NF-kB (Fortin et al., 2004; Varin et al., 2003). Notably, NF-kB activation is 
essential for robust proviral transcription (Nabel and Baltimore, 1987). The 
majority of HIV-1 and SIV Nefs were shown to increase NF-kB activity early 
during the viral life cycle, which is from viral entry to the expression of Tat, Rev 
and Nef (Sauter et al., 2015). Nef promotes NFAT-dependent gene expression, 
and requires an intact SH3 binding domain for this activity (Manninen et al., 
2001). 
 Nef modulates the apoptosis of infected cells and bystander cells. HIV-1 
infection leads to enhanced apoptosis predominately in bystander cells but not in 
productively infected cells (Finkel et al., 1995). Nef promotes the killing of 
bystander cells through the induction of Fas ligand (FasL) expression on the 
surface of HIV-1 infected cells (Xu et al., 1997, 1999). The subsequent 
interaction of FasL with Fas (CD95) expressed on neighboring cells, including on 
CTLs, leads to bystander cell killing, which is another mechanism of immune 
evasion by HIV-1. By inhibiting apoptosis signaling regulating kinase 1 (ASK1), 
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Nef inhibits both Fas- and TNFa-mediated apoptosis in the HIV-1-infected host 
cell (Geleziunas et al., 2001). 
 
Nef enhances the infectivity of progeny virions  
Nef enhances the specific infectivity of progeny virions, but the 
mechanism remained mysterious for decades. Reduction of CD4 expression on 
the producer cell by Nef is reported to elevates viral infectivity (Aiken and Trono, 
1995; Chowers et al., 1994; Miller et al., 1995). However, effects of Nef on viral 
infectivity can be observed in even CD4-negative producer cells. Thus, Nef must 
serve another role (Pandori et al., 1998). 
The recent identification of the antiviral host factors SERINC5 and 
SERINC3 addresses this problem. In the absence of Nef, the multipass 
transmembrane proteins SERINC3 and SERINC5 are incorporated into progeny 
virions and restrict HIV-1 infectivity (Matheson et al., 2015; Rosa et al., 2015; 
Usami et al., 2015). Nef enhances HIV infectivity by removing SERINCs from the 
plasma membrane, which prevents their incorporation into progeny HIV-1 virions 
(Usami et al., 2015). SERINC3 and SERINC5 will be discussed in detail in 
Chapter II. 
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Figure 1.11. The activities of Nef in infected cells.  
Nef downmodulates MHC-I, CD4, CD28, CXCR4, and CD3 (only HIV-2 and 
SIVs) from the surface of infected CD4+ T cells by recruiting them to the 
endocytic machinery via interactions with adaptor protein complexes or by 
rerouting them to endosomes. Furthermore, Nef interacts with cellular kinases 
and induces downstream signaling events to modulate T cell activation; to 
activate NF-AT, NF-kB, and AP-1; and to induce the transcription of death 
receptors. Nef also directly enhances the infectivity of progeny virions.  
Reprinted and adapted with permission from Elsevier (Malim and Bieniasz, 
2012).  
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Summary of dissertation 
 
 The work presented in the following chapters addresses critical gaps in 
our understanding of the newly identified antiretroviral host factor SERINC5 and 
of its interplay with Nef. First, in Chapter II, the antiviral activity of SERINC5 
orthologs and their counteraction by Nef are elucidated. These studies 
demonstrate that the anti-HIV-1 activity is a conserved property of widely 
divergent SERINC5 proteins. However, their sensitivity to Nef is not 
conserved. Nef sensitivity can be transferred by exchanging an intracellular loop 
region. Human SERINC5 can be modified to restrict HIV-1 even in the presence 
of Nef. Next, Chapter III focuses on determinants required for the anti-HIV activity 
of SERINC5. Work presented in this chapter demonstrates that the determinants 
in SERINC5 governing the antiretroviral activity are not confined to one domain. 
Extracellular loop 5 in SERINC5 is a hotspot region that determines the Env-
dependent antiretroviral activity of SERINC5. Chapter IV provides an in-depth 
discussion of these results, their relevance, and outlines future experiments that 
will continue to illuminate molecular mechanisms of intrinsic antiviral immunity.  
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Chapter II. 
A long cytoplasmic loop governs the sensitivity of SERINC5 to 
Nef 
 
Abstract 
Recent studies have identified the multipass transmembrane proteins 
SERINC3 and SERINC5 as antiviral proteins that are incorporated into Nef-
deficient HIV-1 virions and counteracted by Nef (Rosa et al., 2015; Usami et al., 
2015). SERINC5, in particular, can dramatically inhibit the infectivity of Nef-
deficient HIV-1.  HIV-1 Nef removes SERINC3 and SERINC5 from the cell 
surface and prevents their incorporation into progeny virions. In contrast, Nef 
increases the cell surface expression of SERINC1, indicating that SERINC3 and 
SERINC5 are selectively downregulated (Matheson et al., 2015). We now report 
that the anti-HIV-1 activity but not the sensitivity to Nef is conserved among 
vertebrate SERINC5 proteins. However, a Nef-resistant SERINC5 became Nef-
sensitive when its intracellular loop 4 (ICL4) was replaced by that of Nef-sensitive 
human SERINC5. Conversely, human SERINC5 became resistant to Nef when 
its ICL4 was replaced by that of a Nef-resistant SERINC5. In general, ICL4 
regions from SERINCs that exhibited resistance to a given Nef conferred 
resistance to the same Nef when transferred to a sensitive SERINC, and vice 
versa. Importantly, our results establish that human SERINC5 can be modified to 
restrict HIV-1 infectivity even in the presence of Nef. 
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Introduction 
 
The discovery of SERINC5. 
Nef was noted to enhance the specific infectivity of progeny virions more 
than 20 years ago (Aiken and Trono, 1995; Chowers et al., 1994; Miller et al., 
1995). This function of Nef requires its presence during virus production, but Nef 
has no detectable effect on the encapsidation of the genomic viral RNA, the 
incorporation of Env, or the morphology or stability of the mature core (Aiken and 
Trono, 1995; Forshey and Aiken, 2003; Schwartz et al., 1995). Nevertheless, Nef 
increases the efficiency of reverse transcription in target cells (Aiken and Trono, 
1995; Chowers et al., 1995; Schwartz et al., 1995). The effects of Nef on HIV-1 
infectivity are determined by variable HIV-1 Env regions (Usami and Gottlinger, 
2013). It also involves the interaction of Nef with the GTPase Dynamin-2, a 
critical regulator of clathrin-mediated endocytosis (Pizzato et al., 2007; Usami et 
al., 2014). In addition, glycosylated Gag protein (glycoGag) of MLV shares the 
ability of enhancing HIV-1 infectivity in a similar manner to Nef, despite sharing 
no sequence homology with Nef (Pizzato, 2010).  
Several groups identified the host factors attributable to the enhancement 
of viral infectivity by Nef, which are SERINC3 and SERINC5 (Matheson et al., 
2015; Rosa et al., 2015; Usami et al., 2015). Usami and colleagues conducted a 
proteomic analysis of purified virions produced by T lymphoid cells infected with 
wild-type or Nef-deficient HIV-1NL43 (Usami et al., 2015). They found that 
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SERINC3 was the only protein that was identified in Nef-deficient virions but not 
in wild-type virions, or in virions produced in the presence of MLV glycoGag. 
Furthermore, they found that the incorporation particularly of SERINC5 into 
progeny virions dramatically inhibited their infectivity, and that Nef counteracted 
these effects. Rosa et al. and colleagues compared the transcriptomes of 
producer cell lines in which NefNL4-3 caused a differential enhancement of viral 
infectivity (Rosa et al., 2015). The rationale for this approach was that the effects 
of Nef were expected to correlate with the levels of expression of a potential anti-
viral factor. They found that the levels of the SERINC5 transcript correlated most 
closely with the enhancement of viral infectivity by Nef. Both of the groups used 
knockout/knockdown and reconstitution approaches to show that SERINC5 is in 
particular accounts for the infectivity enhancement function of Nef (Rosa et al., 
2015; Usami et al., 2015).  
 
SERINC protein family. 
There was limited information about the function of SERINC proteins 
before the identification of its restriction of HIV-1 infectivity. SERINC proteins 
were reported to facilitate the incorporation of serine in the biosynthesis of 
sphingolipids and phosphatidylserine when ectopically expressed in Escherichia 
coli and yeast (Inuzuka et al., 2005). It is legitimate to hypothesize that SERINC5 
inhibits HIV-1 by altering the composition of lipid membranes of progeny virions. 
However, a recent study disputed this model by showing no significant alterations 
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in the steady-state lipid composition of producer cells and HIV particles bearing 
or lacking SERINC5 (Trautz et al., 2017). Chapter III will discuss the function of 
SERINC5 and how it inhibits HIV-1 infection in more detail. In addition to the 
function, the atomic-level structure of SERINC proteins is so far poorly studied. 
The putative secondary structure of SERINC proteins indicates that they contain 
10-12 transmembrane domains, which poses significant challenges for structural 
studies. 
There are five members in SERINC protein family, SERINC1-5. Only 
SERINC3 and SERINC5 exhibit effective antiretroviral activity, of which the latter 
inhibits the infectivity of HIV-1 to a considerably larger extent (Rosa et al., 2015; 
Schulte et al., 2018; Usami et al., 2015). SERINC3 and SERINC5 are both 
counteracted by Nefs from different clades, with an exception that SERINC3 is 
immune to the downregulation by NefSF2 (Usami et al., 2015). The ability to inhibit 
HIV-1 infectivity is conserved among primate and rodent SERINC5 proteins 
(Heigele et al., 2016). In contrast to most of the host restriction factors, such as 
APOBEC3F/G (Sawyer et al., 2004), TRIM5α (Sawyer et al., 2007), SAMHD1, 
and BST-2, primate SERINC5 orthologs do not display the signatures of an 
evolutionary arms race with viral pathogens (Murrell et al., 2016), which is 
consistent with their highly conserved primary sequences.  
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Nef-mediated downregulation of surface proteins. 
Nef downregulates important immune receptor proteins by recruiting them 
to the endocytic machinery or by rerouting them to lysosomes for degradation 
(reviewed in Roeth and Collins, 2006). Nef hijacks the clathrin-associated 
complex AP-2 to induce the internalization of the viral receptor CD4 (Aiken et al., 
1994; Garcia and Miller, 1991; Greenberg et al., 1997), while it exploits AP-1 to 
downregulate MHC-I and tetherin (Le Gall et al., 1998; Zhang et al., 2009). The 
heterotetrameric clathrin-associated complexes (AP-1, AP-2, AP-3, and AP-4) 
are components of vesicle coats that mediate intracellular trafficking. APs 
selectively recruit proteins by binding to canonical motifs in the cytoplasmic 
domains. The AP-2 complex harbors a recognition site for the tyrosine-based 
sorting motif Yxxf in the µ2 subunit and a recognition site for the dileucine-based 
sorting motif ExxLf in the s2/a unit (in which x is any amino acid, and f 
represents a large hydrophobic amino acid, either L, I, V, M or F). In addition, the 
specificity of AP recruitment relies on the subcellular distribution of AP 
complexes. AP-1 localizes to the TGN, while AP-2 localizes to the inner side of 
the plasma membrane. A dileucine motif and two diacidic motifs in the C-terminal 
flexible loop of Nef are required for the downregulation of CD4 (Craig et al., 
1998). In contrast, the dileucine motif is dispensable for the downregulation of 
MHC-I (Mangasarian et al., 1999). 
Specific motifs in the cytoplasmic tails of surface proteins downregulated 
by Nef determine the selectivity and efficiency of Nef function. Nef selectively 
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downregulates HLA-A and HLA-B without affecting HLA-C or HLA-E (Cohen et 
al., 1999; Le Gall et al., 1998), which protects the infected cells from NK cell-
mediated killing (Cohen et al., 1999), and CTL recognition. The cytoplasmic tail 
of MHC-I governs responsiveness to the downregulation by Nef, and specific 
cytoplasmic tail residues (Y321, D328 and A325) are required for Nef activity 
(Cohen et al., 1999). These required residues are present in HLA-A and HLA-B 
allotypes. However, HLA-C and HLA-E that do not respond to Nef lack one or 
more of these residues and fail to bind Nef (Cohen et al., 1999; Le Gall et al., 
1998).  
Structures of Nef in complex with target proteins and AP complexes help 
to understand the mechanism of downregulation mediated by Nef (Manrique et 
al., 2017; Shen et al., 2015). For instance, a recent structural study illuminates 
why only HIV-2 and SIV Nefs, but not HIV-1 Nef, can downregulate CD3 
(Manrique et al., 2017). In particular, the study shows that HIV-1 Nef lacks an N-
terminal tyrosine motif that is required for the internalization of CD3 by Nef 
(Manrique et al., 2017). Another structural study shows that HIV-1 Nef hijacks 
clathrin by stabilizing a complex between AP-1 and the small guanosine 
triphosphatase Arf1 (Shen et al., 2015). 
Despite the use of different molecular mechanisms, Nef and Vpu possess 
overlapping functions of regulating cell surface proteins (Haller et al., 2014). Most 
of the SIVs and the O group of HIV-1 use their Nefs to counteract tetherin, while 
HIV-1 M strains use Vpu for the same function (Sauter et al., 2009; Zhang et al., 
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2009). A recent study concluded that Vpu does not counteract SERINC5 
(Heigele et al., 2016). 
  
Downregulation of SERINC5 by Nef. 
The machinery of SERINC5 downregulation requires the interaction of Nef 
with the clathrin adaptor complex AP-2 (Pizzato et al., 2007; Rosa et al., 2015). 
In particular, the highly conserved dileucine-based sorting motif (ExxxLL) in the 
C-terminal loop of HIV-1 Nef is required for the downregulation of SERINC5 
(Heigele et al., 2016; Manrique et al., 2017; Rosa et al., 2015; Trautz et al., 
2016). In addition to the dileucine motif, three additional charged residues, 
ERE177, in the C-terminal loop of Nef are indispensable for SERINC5 
antagonism (Heigele et al., 2016). These residues are also critical for the 
downregulation of CD4, but not of MHC-I (Sauter et al., 2015). In general, Nef 
residues essential for SERINC5 antagonism are also essential for CD4 
downregulation by Nef (Trautz et al., 2016). The findings are perhaps not 
surprising, since the downregulation of CD4 and of SERINC5 by Nef both 
dependent on the adaptor complex AP-2.  
Interestingly, not all SIV Nefs require a ExxxLL motif for downregulating 
SERINC5. The SIVcol Nef, which lacks a canonical ExxxLL motif, potently 
antagonizes SERINC5, which suggests a convergent evolution of SERINC5 
antagonism (Heigele et al., 2016). Interestingly, a phylogenetic study indicates a 
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correlation between the potency of SERINC5 antagonism by Nef and the 
prevalence of SIVs in their natural hosts (Heigele et al., 2016).  
Nef selectively downregulates SERINC3 and SERINC5 but not SERINC1 
from the cell surface (Matheson et al., 2015). Furthermore, the effects of HIV-1 
Nef proteins on SERINC3 and SERINC5 are strain-dependent. For instance, the 
Nef proteins of the primary HIV-1 isolates 97ZA012 and 93BR020 strongly inhibit 
the incorporation of SERINC3 and SERINC5 into virions; in contrast, the Nef 
protein of the T cell line-adapted strain SF2 is only active against SERINC5 
(Usami et al., 2015). Thus, Nef proteins can discriminate between different 
SERINC family members. This is reminiscent of the selective recognition of 
distinct MHC-I allotypes (Cohen et al., 1999). Thus, it is important to understand 
which domains in SERINC5 determine its recognition and downregulation by Nef. 
 
Summary 
Recent studies have identified the multipass transmembrane proteins 
SERINC3 and SERINC5 as antiviral proteins that are incorporated into Nef-
deficient HIV-1 virions. Nef counteracts the antiretroviral activity of SERINC5 by 
removing it from the cell surface, and thus prevents its incorporation into progeny 
virions (Rosa et al., 2015; Usami et al., 2015). It has been shown that the 
downregulation of SERINC5 requires the interaction of Nef and clathrin-
associated AP-2 complex (Pizzato et al., 2007; Rosa et al., 2015). SERINC5 
downregulation requires a dileucine motif in Nef, and other Nef residues that are 
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recognized by AP-2 (Heigele et al., 2016; Manrique et al., 2017; Rosa et al., 
2015; Trautz et al., 2016). Moreover, Nef selectively downregulates some 
SERINC proteins but does not affect others. However, the determinants that 
govern sensitivity to Nef have not been identified. 
We now show that an intracellular loop of human SERINC5 confers 
sensitivity to widely divergent Nefs in the context of a Nef-resistant vertebrate 
SERINC5, and also confers sensitivity to NefSF2 in the context of human 
SERINC3, which is normally resistant to this particular Nef. Importantly, human 
SERINC5 acquires resistance against Nefs from different HIV-1 clades when this 
intracellular loop is replaced by the corresponding region from a Nef-resistant 
SERINC5. Taken together, our results identify a major determinant of Nef 
responsiveness, and establish that human SERINC5 can be made resistant to 
Nef-induced downregulation. 
 
 
Results 
 
The anti-viral activity of SERINC5 proteins is conserved, but their responsiveness 
to Nef differs.  
Most of the host antiretroviral factors are important determinants of viral 
host range and cross-species transmission (Gaddis et al., 2004; Keckesova et 
al., 2006). HIV-1 evades their potent inhibitory activity in human cells. But the 
ability of HIV-1 to replicate in non-human cells is often severely compromised 
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due to the host factors. To test whether the ability to inhibit HIV-1 infectivity is 
conserved among SERINC5 proteins, we used 293T cells to produce HIV-1 virus 
in the presence of exogenous SERINC5 proteins. Importantly, 293T cells express 
very little endogenous SERINC5. To generate progeny virus capable of only a 
single cycle of replication, we used an Env-deficient HIV-1 mutant, and Env was 
provided in trans from a separate plasmid.  
As little as 100 ng of a relatively weak (pBJ5-based) SERINC5 expression 
plasmid is sufficient to potently inhibit the single cycle infectivity of Nef− HIV-1 
virions (Usami et al., 2015). Under the same conditions, mouse SERINC5 
reduced the specific infectivity of Nef− HIV-1 virions produced in 293T cells to a 
similar extent (40- to 50-fold) as human SERINC5 (Figure 2.1A). Zebrafish 
(Danio rerio) SERINC5, which is only 61% identical to human SERINC5, reduced 
progeny virus infectivity 13- or 21-fold when 100 or 500 ng expression vector 
were used, respectively (Figure 2.1A).  
 Next, we examined the sensitivities of mouse and zebrafish SERINC5 to 
NefSF2, which selectively inhibits the incorporation of human SERINC5 into HIV-1 
virions (Usami et al., 2015). While the inhibitory effect of mouse SERINC5 on 
Nef− HIV-1 produced in 293T cells was clearly counteracted by NefSF2 expressed 
in trans, the effect of zebrafish SERINC5 was unaffected by NefSF2 (Figure 
2.1B). We infer that widely divergent SERINC5 proteins share the ability of 
human SERINC5 to inhibit HIV-1 infectivity, but not necessarily its sensitivity to 
Nef. 
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Figure 2.1. Anti-HIV-1 activity but not responsiveness to Nef is conserved 
among SERINC5 orthologs. 
(A) Human, mouse, and zebrafish SERINC5 proteins share the ability to inhibit 
the specific infectivity of HIV-1 progeny virions. The amount of transduced 
plasmids of SERINC5 for the infectivity assay was labeled in the figure.  
(B) NefSF2 expressed in trans in virus producer cells counteracts the effect of 
exogenous mouse but not zebrafish SERINC5 on Nef‒ HIV-1 progeny virion 
infectivity. Bar graphs represent the mean + SD from 3 biological replicates. The 
amount of transduced plasmids of SERINC5 for the infectivity assay was 100 ng.  
 
 
 
 
Transfer of Nef sensitivity to a Nef-resistant SERINC5.  
The differential responsiveness of vertebrate SERINC5 proteins to Nef 
provided a potential tool to identify determinants that confer sensitivity to Nef. 
Because zebrafish SERINC5 was somewhat less active against Nef− HIV-1 than 
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human SERINC5, we also tested the SERINC5 protein of the Western clawed 
frog (Xenopus tropicalis). Frog SERINC5 expressed from pBJ5 inhibited the 
single cycle infectivity of Nef− HIV-1 progeny virions with a potency comparable 
to that of human SERINC5 (Figure 2.2A). However, whereas human SERINC5 
is efficiently counteracted by NefSF2 (Usami et al., 2015), the inhibitory effect of 
frog SERINC5 expressed from pBJ5 on Nef− HIV-1 was unaffected by NefSF2 
(Figure 2.2C). Even when expressed from pBJ6, which lacks an SV40 origin 
required for episomal amplification as well as SV40 enhancer sequences (Rosa 
et al., 2015), frog SERINC5 reduced the specific infectivity of Nef− HIV-1 more 
than 40-fold, and this inhibitory effect largely persisted in the presence of NefSF2 
expressed in trans (Figure 2.2C). In the absence of exogenous SERINC5, the 
effect of NefSF2 on the infectivity of Nef− HIV-1 virions was quite modest in these 
experiments (Figure 2.2C), perhaps because 293T cells express only low levels 
of endogenous SERINC5 (Usami et al., 2015). 
 We subsequently used frog SERINC5 as a recipient of human SERINC5 
sequences to identify determinants that confer sensitivity to NefSF2. The TMHMM 
membrane protein topology prediction method (Krogh et al., 2001) predicts that 
SERINC5 has 10 transmembrane helices, and our previous findings indicate that 
the loop connecting helices 7 and 8 is surface-exposed (Usami et al., 2015). This 
in turn suggested that the loop connecting helices 8 and 9 represents the fourth 
and longest intracellular loop (Figure 2.2B). To examine the role of this region, 
we replaced the ICL4 of frog SERINC5 by that of human SERINC5 (Figure 
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2.2B). The resulting fS5/hS5-ICL4 chimera largely retained the ability of frog 
SERINC5 to inhibit the specific infectivity of Nef− HIV-1 progeny virions, but lost 
much of its resistance to NefSF2 expressed in trans (Figure 2.2C). This 
observation applied to SERINCs expressed both from pBJ5 and from the very 
weak pBJ6 expression plasmid. Thus, the transfer of the ICL4 of human 
SERINC5 was sufficient to confer substantial sensitivity to NefSF2.     
 As previously reported (Usami et al., 2015), the incorporation of 
haemagglutinin (HA)-tagged human SERINC5 into progeny virions was strongly 
inhibited by NefSF2 (Figure 2.2D, lanes 1 and 2). In contrast, the incorporation of 
frog SERINC5 was only slightly affected by NefSF2 (lanes 3 and 4). Finally, the 
effect of NefSF2 on the incorporation of the fS5/hS5-ICL4 chimera resembled its 
effect on human SERINC5 (lanes 5 and 6). We conclude that the transfer of the 
ICL4 was sufficient to allow NefSF2 to significantly inhibit both the anti-HIV-1 effect 
and the virion incorporation of frog SERINC5. 
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Figure 2.2. Transfer of human SERINC5 ICL4 is sufficient to confer Nef 
responsiveness to frog SERINC5. 
(A) Frog SERINC5 is as potent as human SERINC5 in inhibiting the single-round 
infectivity of Nef‒ HIV-1 progeny virions. The amounts of SERINC5 plasmids 
differed in left and right panels. 
(B) Schematic illustration of the parental SERINC5 proteins and of the chimera 
examined. 
(C) The effect of frog SERINC5 on Nef‒ HIV-1 progeny virion infectivity is largely 
resistant to NefSF2 but becomes sensitive upon replacement of its ICL4 by that of 
human SERINC5. The expression plasmids of SERINC5 used for the left panel 
were pBJ5-based, which the ones for the right panel were pBJ6-based.  
(D) Western blots showing the effects of NefSF2 on the incorporation of human, 
frog and chimeric SERINC5 into Nef‒ HIV-1 virions. 
Bar graphs represent the mean + SD from 3 biological replicates. 
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The ICL4 of human SERINC5 confers sensitivity to widely divergent Nefs.  
Unlike NefSF2 (clade B), which selectively inhibits the incorporation of 
human SERINC5 into HIV-1 virions, Nef97ZA012 (clade C) also inhibits the 
incorporation of human SERINC3 (Usami et al., 2015). Nevertheless, the 
inhibitory effect of frog SERINC5 on HIV-1 infectivity was essentially unaffected 
by Nef97ZA012 (Figure 2.3A), as was the incorporation of frog SERINC5 into HIV-1 
virions (Figure 2.3B). In contrast, Nef97ZA012 enhanced the specific infectivity of 
Nef− HIV-1 produced in the presence of the fS5/hS5-ICL4 chimera about 13-fold 
(Figure 2.3A), and strongly inhibited the incorporation of the chimeric protein 
(Figure 2.3B). Thus, the ICL4 of human SERINC5 conferred sensitivity to HIV-1 
Nefs from different subtypes.   
Because the ability to counteract SERINC5 is conserved among all 
primate lentiviral lineages (Heigele et al., 2016), we additionally examined the 
effects of SIV Nefs. SIVmac239 Nef increased the specific infectivity of Nef− HIV-1 
produced in the presence of frog SERINC5 or of the fS5/hS5-ICL4 chimera 17- 
and 27-fold, respectively (Figure 2.3C). Thus, SIVmac239 Nef counteracted even 
unmodified frog SERINC5. In contrast, unmodified frog SERINC5 was largely 
resistant to the Nef proteins of SIVagm155 and SIVagm677, and the transfer of the 
ICL4 of human SERINC5 substantially increased its sensitivity to these Nefs 
(Figures 2.3D and 2.3E). Overall, these findings demonstrate that the ICL4 of 
human SERINC5 can confer sensitivity to Nefs from widely divergent primate 
lentiviruses. 
 69 
 
 
 
Figure 2.3. The ICL4 of human SERINC5 confers sensitivity to widely 
divergent Nefs.  
(A) The inhibitory effect of frog SERINC5 on HIV-1 infectivity is resistant to HIV-1 
subtype C Nef97ZA012 but becomes sensitive in the presence of the ICL4 of human 
SERINC5. 
(B) Western blots showing that Nef97ZA012 does not affect the incorporation of frog 
SERINC5 into Nef‒ HIV-1 virions but strongly inhibits the incorporation of a 
chimeric version that harbors the ICL4 of human SERINC5. 
(C-E) Effects of SIV Nef proteins on the inhibition of HIV-1 infectivity by frog 
SERINC5 and by a version that harbors the ICL4 of human SERINC5.  
In all cases, the histograms represent the mean + SD from three measurements. 
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The ICL4 of frog SERINC5 confers resistance to Nef.  
 
The results described above showed that the fS5/hS5-ICL4 chimera 
gained sensitivity to various Nefs. We next made the reciprocal hS5/fS5-ICL4 
chimera bearing the ICL4 of frog SERINC5 in the context of human SERINC5 
(Figure 2.4A), in order to test the hypothesis that the ICL4 of human SERINC5 is 
necessary for its Nef responsiveness. The hS5/fS5-ICL4 chimera inhibited the 
infectivity of Nef− HIV-1 virions carrying EnvHXB2 as potently as authentic human 
SERINC5 (Figures 2.4B and 2.4C). Although the infectivity of Nef− HIV-1 virions 
carrying the relatively SERINC5-resistant EnvJRFL was inhibited to a lesser extent 
as expected (Rosa et al., 2015), the hS5/fS5-ICL4 chimera again was at least as 
potent as human SERINC5 (Figure 2.4D), confirming that it retained full anti-HIV 
activity.  
Crucially, whereas NefSF2 increased the infectivity of progeny virions 
carrying EnvHXB2 about 37-fold in the presence of exogenous human SERINC5, 
only a 2-fold increase was observed in the presence of the hS5/fS5-ICL4 chimera 
(Figure 2.4B). Furthermore, similar results were obtained with Nef97ZA012 (Figure 
2.4C). Consistent with these observations, the incorporation of the hS5/fS5-ICL4 
chimera into HIV-1 virions was not inhibited by NefSF2, and only moderately 
reduced by Nef97ZA012 (Figure 2.4E). As expected, both Nef proteins strongly 
inhibited the incorporation of authentic human SERINC5 (Figure 2.4E). We 
conclude that the hS5/fS5-ICL4 chimera exhibits marked resistance to HIV-1 Nef 
proteins.  
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Figure 2.4. The ICL4 of frog SERINC5 confers resistance to Nef. 
(A) Schematic illustration of the parental SERINC5 proteins and of the chimera 
examined. 
(B) Human SERINC5 bearing the ICL4 of frog SERINC5 remains fully capable of 
inhibiting the infectivity of Nef‒ HIV-1 virions but exhibits strong resistance to a 
clade B HIV-1 Nef (NefSF2). 
(C) The SERINC5 chimera also exhibits resistance to a clade C HIV-1 Nef 
(Nef97ZA012). 
(D) The SERINC5 chimera inhibits the infectivity of Nef‒ HIV-1 virions carrying a 
relatively resistant HIV-1 Env at least as well as the wild-type human SERINC5. 
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(E) Western blots showing the effects of clade B and C HIV-1 Nefs on the 
incorporation of human SERINC5 and of the SERINC5 chimera into Nef‒ HIV-1 
virions.  
Bar graphs represent the mean + SD from 3 biological replicates. 
 
 
 
 
 
 
 
Evidence for a physical interaction between Nef and the ICL4 of human 
SERINC5.  
 
A pronounced tendency to aggregate makes it challenging to  examine 
whether SERINC5 and Nef interact via co-immunoprecipitation. Thus,  we tested 
whether SERINC5 affects the virion-association of the LL164,164AA AP-2 binding 
site mutant of NefLAI (Figure 2.5A), which does not counteract SERINC5 (Rosa et 
al., 2015). The mutant Nef was more abundant in HIV-1 virions produced in the 
presence of the fS5/hS5-ICL4 chimera rather than of frog SERINC5 (Figure 
2.5B). Since frog SERINC5 and the fS5/hS5-ICL4 chimera were incorporated 
about equally in the absence of a functional Nef (Figure 2.3B), this finding 
provides indirect evidence for a physical interaction between Nef and the ICL4 of 
human SERINC5. 
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Figure 2.5. The physical interaction between Nef and the ICL4 of human 
SERINC5.  
(A)  Schematic illustration of NefLAI mutant which is disabled of binding to AP2. 
(B) Western blots showing that a NefLAI mutant unable to counteract SERINC5 
(LL164,165AA) is more abundantly incorporated into HIV-1 virions produced in the 
presence of frog SERINC5 bearing the ICL4 of human SERINC5. The virions 
lacked protease to prevent the cleavage of Nef. 
 
 
 
 
ICL4 of human SERINC2 confers resistance to NefSF2, but not Nef97ZA012. 
To further investigate the role of the ICL4 in other members of SERINC 
family, we replaced the ICL4 of human SERINC5 by that of human SERINC2, 
which exhibits no sequence similarity in this region. Human SERINC2 does not 
exhibit antiretroviral activity, and is resistant to downregulation by NefSF2.  
The resulting hS5/hS2-ICL4 chimera (Figure 2.6A) inhibited the specific 
infectivity of Nef− HIV-1 virions, albeit less potently than authentic human 
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SERINC5 (Figure 2.6B). In this experiment, NefSF2 increased virion infectivity 
more than 50-fold in the presence of exogenous human SERINC5, but less than 
2-fold in the presence of the chimera. Furthermore, the incorporation of the 
hS5/hS2-ICL4 chimera into HIV-1 virions was essentially resistant to NefSF2 
(Figure 2.6C).  
To directly test the surface expression of SERINC5 chimeric proteins and 
how Nef regulates it, we used SERINC5(iHA), which contains an internal HA tag 
within an extracellular loop (Usami et al., 2015). Flow cytometry revealed that the 
surface expression of SERINC5(iHA) was not compromised when its ICL4 was 
replaced by that of SERINC2, and that the ICL4 swap conferred resistance to 
down-regulation by NefSF2 (Figure 2.7). Together, these results establish that the 
ICL4 swap markedly reduced the sensitivity of human SERINC5 to NefSF2. 
 During the course of these experiments, we observed that the 
incorporation of human SERINC2 into Nef-deficient HIV-1 virions, although 
unaffected by NefSF2, is inhibited by Nef97ZA012 (Figure 2.6D). Similarly, the 
incorporation of the hS5/hS2-ICL4 chimera, while unaffected by NefSF2, was 
clearly inhibited by Nef97ZA012 (Figure 2.6E). Since the hS5/fS5-ICL4 chimera, 
which differs only in the ICL4, was resistant to Nef97ZA012 (see Figure 2.4C), 
these findings raise the possibility that Nef97ZA012 recognizes a determinant within 
the ICL4 of SERINC2. Additionally, these findings suggest that only ICL4 regions 
derived from SERINCs that exhibit resistance to a given Nef confer resistance to 
the same Nef when transferred to a sensitive SERINC. 
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Figure 2.6. The ICL4 of human SERINC2 confers resistance to NefSF2 but 
not Nef97ZA012. 
(A) Schematic illustration of the parental human SERINC proteins and of the 
chimera examined. 
(B) The inhibitory activity of human SERINC5 bearing the ICL4 of human 
SERINC2 on Nef‒ HIV-1 progeny virion infectivity is largely resistant to NefSF2. 
Bar graphs represent the mean + SD from 3 biological replicates. 
(C) Western blots showing that the incorporation of the SERINC chimera into 
Nef‒ HIV-1 virions is largely unaffected by NefSF2 expressed in trans. The 
incorporation of the chimera was analyzed in duplicate to document 
reproducibility. 
(D) Western blots showing that the incorporation of human SERINC2 into Nef‒ 
HIV-1 virions is unaffected by NefSF2 but inhibited by Nef97ZA012. 
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(E) Western blots showing that Nef97ZA012 inhibits the incorporation of human 
SERINC5 bearing the ICL4 of human SERINC2 into Nef‒ HIV-1 virions. 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2.7. Swapping the ICL4 of human SERINC5 for that of human 
SERINC2 confers resistance to down-regulation by NefSF2.  
JurkatTAg S5 -/- cells stably expressing SERINC5(iHA) or the S5/hS2-ICL4(iHA) 
chimera together with NefSF2 were surface-stained with anti-HA antibody and 
analyzed by flow cytometry. Per cent fractions of cells expressing SERINC5(iHA) 
or the S5/hS2-ICL4(iHA) chimera on the surface are indicated. 
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Transfer of sensitivity against NefSF2 to SERINC3.  
SERINC3 is another member of the SERINC family that exhibits 
antiretroviral activity, though this activity is much weaker than that of SERINC5. 
Unlike other HIV-1 Nefs, NefSF2 has no effect on the incorporation of SERINC3 
into HIV-1 virions (Usami et al., 2015). To examine whether the ICL4 of 
SERINC5 confers sensitivity to NefSF2 in the context of human SERINC3, we 
generated the hS3/hS5-ICL4 chimera, which harbors the ICL4 of human 
SERINC5 in a human SERINC3 background (Figure 2.8A). While the 
incorporation of authentic human SERINC3 was unaffected by NefSF2 as 
previously reported (Usami et al., 2015), the incorporation of the chimera was 
strongly inhibited (Figure 2.8B), confirming the role of the ICL4 in determining 
Nef sensitivity. 
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Figure 2.8. Human SERINC3 acquires sensitivity to NefSF2 in the presence 
of the ICL4 of human SERINC5. 
(A) Schematic illustration of the parental human SERINC proteins and of the 
chimera examined. 
(B) Western blots showing that NefSF2 inhibits the incorporation of human 
SERINC3 into Nef‒ HIV-1 virions only upon replacement of its ICL4 by that of 
human SERINC5. 
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Point mutations in the ICL4 of human SERINC5 confer resistance to Nef. 
Although Nef typically targets dileucine- or tyrosine-based sorting motifs, 
such motifs are not evident within the ICL4 of human or mouse SERINC5 
(Figure 2.9A). To examine which region of the ICL4 determines sensitivity to 
Nef, we generated versions of Nef-resistant frog SERINC5 that have relatively 
poorly conserved segments replaced by the corresponding human SERINC5 
sequences (Figure 2.9A). We observed that the transfer of ICL4 residues 9-26 
but not of ICL4 residues 26-41 of human SERINC5 significantly increased the 
sensitivity of frog SERINC5 to NefSF2 (Figure 2.9B). Within the 9-26 segment, a 
leucine residue (L350 in human SERINC5) is present in Nef-sensitive but not in 
Nef-resistant SERINC5 proteins (Figure 2.9A). Point mutations that targeted this 
residue (L350A) or another small hydrophobic residue nearby (I353A) reduced 
the sensitivity of human SERINC5 to NefSF2 about 8- and 3-fold, respectively 
(Figure 2.9C). Both mutations together (L350A/I353A) reduced the sensitivity of 
human SERINC5 more than 12-fold, and an 8-fold reduction was observed when 
L350 and I353 were replaced by the corresponding residues in frog SERINC5 
(L350T/I353M) (Figure 2.9C). We also observed that the L350A and 
L350A/I353A mutations rendered the incorporation of human SERINC5 into HIV-
1 virions largely resistant to NefSF2 (Figure 2.9D). These findings confirm the 
crucial role of the ICL4 in Nef sensitivity.   
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Figure 2.9. Point mutations in the ICL4 of human SERINC5 confer 
resistance to Nef. 
(A) Alignment of the ICL4 regions of Nef-sensitive (human, mouse) and Nef-
insensitive (frog, zebrafish) SERINC5 proteins, and schematic illustration of intra-
ICL4 chimeras examined. 
(B) The transfer of human SERINC5 ICL4 residues 9-26 but not of residues 26-
41 to the ICL4 of frog SERINC5 increases its sensitivity to NefSF2. 
(C) Point mutations targeting small hydrophobic amino acids within the ICL4 of 
human SERINC5 reduce the sensitivity of its effect on HIV-1 infectivity to NefSF2. 
(D) Western blots showing the effects of NefSF2 on the incorporation of WT 
human SERINC5 and of ICL4 mutants into Nef‒ HIV-1 virions.  
In all cases, the histograms represent the mean + SD from three measurements. 
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Nef poorly counteracts inhibition of HIV replication by a SERINC5 chimera.  
To investigate the role of SERINC5 and its ICL4-mediated counteraction 
by Nef in HIV-1 replication and spreading, we reconstituted SERINC3+SERINC5 
double-knockout (DKO) JTag cells with human SERINC5 and the chimera 
bearing the ICL4 of frog SERINC5 (hS5/fS5-ICL4) (Figure 2.4A). HIV-1NL43-
based viruses encoding either wild-type or a Nef-deficient version of NefNL43 were 
used to infect cells. Both Nef+ and Nef- HIV-1 were able to replicate in the 
double-knockout cells at comparable rates, while Nef+ virus more robustly 
replicated in cells reconstituted with human SERINC5 compared to Nef- virus 
(Figure 2.10A, B). These observations confirmed that Nef counteracts the 
inhibition of HIV-1 replication by human SERINC5 (Usami et al., 2015).  
DKO cells reconstituted with either human SERINC5 or hS5/fS5-ICL4 
controlled the viral spreading of Nef-deficient HIV-1 for at least 21 days. 
However, Nef+ HIV-1 replication in DKO cells reconstituted with hS5/fS5-ICL4 
was delayed compared to that in human SERINC5-reconstituted DKO cells until 
19 days post-infection, which indicated that the resistance to Nef conferred by 
frog SERINC5 ICL4 led to the inhibition of HIV-1 replication (Figure 2.10A, B). 
However, Nef+ HIV-1 eventually spread in hS5/fS5-ICL4-reconstituted cells 
(Figure 2.10B), which might suggest that additional restriction factor(s) 
counteracted by Nef can suppress viral spreading.  
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Figure 2.10. Nef poorly counteracts inhibition of HIV replication by a 
SERINC5 chimera harboring the frog SERINC5 ICL4. (continued on the next 
page) 
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Effects of Nef on virus spreading in double-knockout JTAg cells lacking 
SERINC3 and SERINC5, SERINC5-reconstituted double-knockout cells, and 
hS5/fS5-ICL4-reconstituted double-knockout cells. The spreading of HIV-1NL43-
based viruses encoding either wild-type or disrupted version of Nef97ZA012 was 
examined by western blotting of cell lysates with anti-CA antibody 12 days or 15 
days after infection with 2 ng ml-1 p24 (A), or by monitoring p24 accumulation in 
the supernatants (B). 
 
 
 
 
 
 
 
 
Discussion 
 
This study shows that widely divergent SERINC5 proteins from different 
vertebrate species share the ability to markedly inhibit the infectivity of Nef− HIV-
1 virions. However, sensitivity to Nef is not conserved and can be transferred to a 
Nef-resistant SERINC5 by exchanging the ICL4 region. In the same manner, 
human SERINC3 can be made sensitive to a particular Nef, supporting the 
crucial role of the ICL4 region in Nef sensitivity. Conversely, our results show that 
the anti-HIV-1 activity of human SERINC5 can be made to persist even in the 
presence of Nef, which might provide a novel strategy to combat HIV-1 
(summarized in Figure 2.11). However, the in vivo significance of the effect of 
Nef on SERINC5 remains to be established.  
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Figure 2.11. A long cytoplasmic loop governs the sensitivity of SERINC5 to 
Nef.  
Nef downregulates human SERINC5 from cell surface and prevents its 
incorporation into progeny virions. hS5-free viruses can successfully infect target 
cells (left panel). In contrast, frog SERINC5 is resistant to counteraction by Nef, 
and incorporated into virions even in the presence of Nef. Progeny virions 
bearing frog SERINC5 fail to infect new target cells (middle panel). Human 
SERINC5 bearing the ICL4 of frog SERINC5 is resistant to Nef downregulation 
and incorporated into progeny virions even in the presence of Nef.    
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The highly conserved antiviral activity of SERINC5. 
The conservation of the anti-HIV activity among vertebrate SERINC5 
proteins indicates that this activity is closely related to the biological function of 
SERINC5, which remains to be elucidated. The conserved antiretroviral activity 
suggested by our studies is in agreement with the computational analysis of 
primary sequences of SERINC5 (Murrell et al., 2016). SERINC5 plays a role in 
the interaction of the host with another retrovirus, equine infectious anemia virus 
(EIAV) (Chande et al., 2016). Similar to HIV-1 Nef counteracting SERINC5, the 
S2 protein of EIAV antagonizes the inhibitory activity of SERINC5 (Chande et al., 
2016). SERINCs have been named for their reported function as carrier proteins 
that facilitate the synthesis of serine-derived lipids (Inuzuka et al., 2005). This 
activity suggested a model in which SERINCs inhibit HIV-1 infectivity by 
modifying the lipid content of progeny virions. However, a recent study argues 
strongly against this hypothesis by showing that SERINC5 does not alter the lipid 
composition of HIV-1 progeny virions or the exposure of phosphatidylserine on 
their surface (Trautz et al., 2017).    
 
The mechanism and machinery of the counteraction of SERINC5 by Nef. 
Usami et al. (Usami et al., 2015) and Pizzato and coworkers (Rosa et al., 
2015) have presented evidence indicating that Nef counteracts SERINC5 by 
preventing its incorporation into HIV-1 virions. More recent work confirmed that 
Nef excludes SERINC5 from virions, but also suggested that Nef additionally 
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inactivates the antiviral activity of any SERINC5 that becomes virion-associated 
even in the presence of Nef as a consequence of overexpression (Trautz et al., 
2016). In our study, the ability of Nef proteins to reduce the incorporation of 
native or chimeric versions of frog or human SERINC5 correlated well with their 
ability to enhance HIV-1 infectivity, which supports the notion that virion exclusion 
is the primary mechanism by which Nef counteracts SERINC5. 
The ability of Nef to counteract human SERINC5 depends on the AP-2 
clathrin adaptor complex (Rosa et al., 2015), whose cargo-binding AP2M1 and 
AP2S1 subunits in particular are more than 95% identical in human, frog, and 
zebrafish. Nef also hijacks clathrin adaptors to downregulate CD4 and MHC-I, 
and in these cases Nef:AP complexes recognize linear epitopes within the 
cytosolic domains of CD4 and MHC-I (Jia et al., 2012; Ren et al., 2014). Our 
results indicate that certain small hydrophobic residues within the ICL4 of human 
SERINC5 are critical for its sensitivity to Nef, and it is tempting to speculate that 
the region containing these residues is also recognized by Nef:AP complexes.  
 
The effect of Nef polymorphism on the counteraction of SERINC5. 
Nearly the entire ICL4 region is predicted to be flexible by the PROFbval 
program (Schlessinger et al., 2006). The apparent flexibility of the ICL4 could 
conceivably facilitate interactions with widely divergent Nef proteins through a 
mechanism involving conformational selection (Boehr et al., 2009). Indeed, our 
data show that the ICL4 of human SERINC5 can confer sensitivity to Nefs from 
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different primate lentiviral lineages. In addition to the canonical sorting motif 
ExxxLL of Nef, an ERE177 sequence within Nef plays a role determining 
SERINC5 antagonism (Heigele et al., 2016). The participation of multiple motifs 
within Nef in its effect on SERINC5 illustrates the importance of overcoming this 
restrictive factor in HIV-1 infection. On the other hand, the mere replacement of 
two adjacent amino acids within the ICL4 of human SERINC5 completely erased 
the sensitivity to Nef (Figure 2.9C). Studies examining polymorphisms within 
SERINC5 in a large population might reveal the role of SERINC5 in HIV-1 
infection. 
The downregulation of immune receptors mediated by Nef benefits viral 
pathogenesis and persistence. Comparison of nef alleles derived from long-term 
nonprogressors and progressors revealed that sequence variations in Nef are 
associated with different stages of infections (Kirchhoff et al., 1999). Primary Nef 
isolates from elite controllers exhibit an impaired ability to downregulate CD4, 
MHC-I, and NKG2D (Alsahafi et al., 2017; Mwimanzi et al., 2013; Toyoda et al., 
2015). Elite controllers are a rare group of infected individuals who 
spontaneously control plasma viremia below 50 RNA copies/ml in the absence of 
ART (reviewed in Deeks and Walker, 2007). The mechanism of elite control 
remains elusive, even though extensive GWAS studies were carried out to 
address this question (reviewed in Walker and Yu, 2013). HLA-B*27 and HLA-
B*57 are associated with protection against disease progression in HIV-1 
infected individuals (Kaslow et al., 1996; Migueles et al., 2000). However, most 
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people with such “protective HLA alleles” nevertheless progress to AIDS. A 
recent study suggested that the ability of Nef to counteract SERINC5 is 
modulated by natural sequence variation as well (CROI 2018). Given that the 
ExxxLL motif is conserved in nef alleles from elite controllers (Kirchhoff et al., 
1999), it is possible that additional motifs characterized in the Heigele et al. paper 
disable the ability to redirect of SERINC5 from the cell surface. If a differential 
downregulation of SERINC5 and of other cell surface molecules by Nef in 
progressors and elite controllers could be verified, this would raise the possibility 
that cellular trafficking is altered in elite controllers.   
 
The role of SERINC5 and its counteraction in viral replication. 
Previous studies have shown that SERINC5 inhibits HIV-1 replication in 
tissue culture, and that Nef counteracts this inhibition (Rosa et al., 2015; Usami 
et al., 2015). We have shown that the Nef-resistant SERINC5 chimera hS5/fS5-
ICL4 inhibits the replication even of Nef+ HIV-1 (Figure 2.10). However, the Nef-
resistant SERINC5 failed to block viral spreading completely. (Figure 2.10). This 
suggests that Nef may serve another, as yet poorly understood role in replication 
and viral spreading of HIV-1, in addition to counteracting SERINC3 and 
SERINC5. Disruption of the actin cytoskeleton was shown to complement the 
ability of Nef to enhance HIV-1 infectivity (Campbell et al., 2004). Further studies 
are needed to examine the underlying mechanisms.   
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Given the conservation of Nef’s ability to counteract human SERINC5 in 
spite of the considerable variability of Nef’s primary sequence, it is legitimate to 
hypothesize that the counteraction of SERINC5 in vivo plays a critical role in 
disease progression and viral pathogenesis. However, the importance of 
SERINC5 in HIV-1 replication and viral persistence has not attracted too much 
attention. HIV cure strategies require an understandings of the mechanism of 
viral persistence and the maintenance of viral reservoir. The intrinsic characters 
of infected cells among CD4 T cell subsets determine the size and fate of latently 
infected lymphocytes (Boritz et al., 2016; Buzon et al., 2014). The expression 
levels of SERINC5 in distinct T cell subsets and tissues have not been examined. 
It is possible that differential levels of SERINC5 in various cell subsets and 
tissues may account for viral persistence.  
To address this question, it is necessary to examine the transcriptional 
levels of SERINC5 in T cell subsets of infected individuals. Since a minor change 
of SERINC5’s level significantly alters its inhibitory effect on HIV-1 infectivity in in 
vitro studies (Rosa et al., 2015; Usami et al., 2015), differential expression levels 
of SERINC5 are potentially of significance. Besides, there is still no effective cell 
surface marker for HIV reservoirs (Abdel-Mohsen et al., 2018; Descours et al., 
2017). The transmembrane protein SERINC5 may provide a promising index for 
locating the rare cells contributing to the HIV reservoir. A limitation of the above 
experimental design is that transcriptional levels do not adequately represent the 
amount of SERINC5 on the cell surface. Additionally, a recent study suggested 
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that SERINC5 within detergent-resistant membranes is preferentially 
downregulated by Nef (Schulte et al., 2018). Thus, the downregulation of 
SERINC5 in HIV-1 infection might not cause a significant change at the total 
transcriptional level.  
 
 
Materials and methods 
 
Cells.  
JTAg, 293T were gifts from G. Crabtree, D. Baltimore. TZM-bl cells were 
obtained from the AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH. JurkatTAg S5 -/- cells were published (Usami et al., 2015). 
 
Analysis of virus infectivity.  
Pseudovirions capable of a single round of replication were produced by 
transfecting 293T cells using a calcium phosphate precipitation method. The cells 
were co-transfected with HXB/Env−/Nef− (1 µg in the experiments shown in 
Figures 2.1A, 2.1B, and 2.2A; 2 µg in all other experiments), a pSVIIIenv-based 
plasmid expressing EnvHXB2 or, where indicated, EnvJRFL (0.1 µg in the 
experiments shown in Figures 2.1A, 2.1B, 2.2A and 2.3D; 0.4 µg in all other 
experiments), and the indicated amounts of pBJ5- or pBJ6-based plasmids 
expressing wild type or chimeric SERINC5 proteins, or with equimolar amounts 
of empty vector. In addition, equal amounts of the nef-deficient pNefFS or of a 
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plasmid expressing an HIV-1 or SIV Nef were co-transfected where indicated (2 
µg in the experiments shown in Figure 2.1B and in the left panel of Figure 2.2C; 
0.5 µg in all other experiments). Supernatants containing progeny virions were 
harvested one day post transfection, clarified by low-speed centrifugation, filtered 
through 0.45 μm pore filters, and then used immediately to infect TZM-bl 
indicator cells in triplicate in 6-well plates. Aliquots of the virus stocks were frozen 
for HIV-1 capsid (p24) antigen quantitation by a standard ELISA. Three days post 
infection, the indicator cells were lysed, and β-galactosidase activity induced as a 
consequence of infection was measured using a kit (E2000; Promega). Values 
were normalized for the amount of p24 antigen present in the supernatants used 
for infection.  
 
Analysis of SERINC incorporation.  
293T cells were co-transfected with 1 µg HXB/Env−/Nef−, pBJ5-based expression 
plasmids for C-terminally HA-tagged SERINCs or SERINC chimeras (0.1 µg, 
unless indicated otherwise), and the nef-deficient control plasmid pNefFS or a 
plasmid expressing an HIV-1 Nef (0.5 μg in the experiments shown in Figures 
2.6E, 2.3B, and 2.8B; 2 μg in the experiments shown in Figures 2.2D, 2.6C, and 
2.6E). Virions released into the medium were pelleted through 20% sucrose 
cushions, and virus- and cell-associated proteins were detected by western 
blotting as described (Accola et al., 2000). Since SERINC proteins are highly 
aggregation-prone (Usami et al., 2015), samples used for the detection of 
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SERINCs were not boiled before loading. The antibodies used were 183-H12-5C 
against HIV-1 CA, and HA.11 (Biolegend) against the HA epitope.  
 
Expression plasmids.  
The env- and nef-deficient HIV-1 provirus HXB/Env−/Nef−, the pSVIIIenv-based 
plasmids expressing EnvHXB2 or EnvJRFL, the pBJ5-based expression plasmids for 
the Nef proteins of HIV-1SF2, HIV-197ZA012, and SIVmac239, the nef-deficient 
control plasmid pNefFS, and the pBJ5-based expression plasmid for human 
SERINC3-HA, human SERINC5, and human SERINC5-HA have been described 
(Dorfman et al., 2002; Helseth et al., 1990; Pizzato et al., 2007; Usami et al., 
2015). A pBJ6-based expression plasmid for human SERINC5 was kindly 
provided by M. Pizzato. The nef genes of SIVagm155 and SIVagm677 were 
amplified from proviral clones and inserted into pBJ5. The coding sequences for 
mouse, zebrafish, and frog SERINC5 were amplified from BC062121, IMAGE 
clone 7650941, and BC044159 (Dharmacon). DNAs encoding mutant and 
chimeric proteins without or with C-terminal HA tags were generated using an 
overlap extension PCR method (Horton et al., 1989) and inserted into pBJ5 or 
pBJ6 downstream of a Kozak sequence. The fS5/hS5-ICL4 chimera has residues 
342-390 of frog SERINC5 replaced by residues 342-389 of human SERINC5. 
The intra-ICL4 chimeras fS5/hS5-ICL4(9-26) and fS5/hS5-ICL4(26-41) have 
residues 342-359 and 359-375 of frog SERINC5 replaced by the corresponding 
residues of human SERINC5. The hS5/fS5-ICL4 chimera has residues 342-389 
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of human SERINC5 replaced by residues 342-390 of frog SERINC5. The 
hS5/hS2-ICL4 chimera has residues 334-389 of human SERINC5 replaced by 
residues 343-388 of human SERINC2. The hS3/hS5-ICL4 chimera has residues 
358-404 of human SERINC3 replaced by residues 335-389 of human SERINC5.  
 
HIV proviral constructs.  
NL4-3/Nefstop, the nef-deficient variant of the prototypic HIV-1NL4-3 used in the 
replication study, has nef codons 31–33 replaced by three consecutive 
premature termination codons. 
 
Retroviral vectors.  
The coding sequence for SERINC5(iHA) (Usami et al., 2015) preceded by a 
Kozak sequence was amplified from pBJ5-SERINC5(iHA) and inserted into the 
retroviral vector MSCVpuro (Clontech). Additionally, a version of the hS5/hS2-
ICL4 chimera that harbors an internal HA tag at the same position as 
SERINC5(iHA) was cloned into MSCVpuro. The coding sequence for HIV-1 
NefSF2 preceded by a Kozak sequence was cloned into MSCVhyg (Clontech), 
yielding MSCVhygNefSF2. A nef-deficient version (MSCVhygNefSF2FS) was 
obtained by generating a frameshift at a unique XhoI site in nef. 
 
Analysis of Nef incorporation.  
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293T cells were co-transfected with 2 µg of the protease-deficient HIV-1 proviral 
construct HXB/VPR+/PR− (Bukovsky and Göttlinger, 1996), 2 µg of a pBJ5-based 
plasmid expressing C-terminally HA-tagged NefLAI with a LL164,165AA mutation 
(Pizzato et al., 2007), and 2 µg of a pBJ5-based plasmid expressing native frog 
SERINC5 (fS5) or a version harboring the ICL4 of human SERINC5 (fS5/hS5-
ICL4).  Virions released into the medium were pelleted through 20% sucrose 
cushions, and virus- and cell-associated proteins were detected by western 
blotting. The antibodies used for western blotting were 183-H12-5C against HIV-
1 CA, and HA.11 (Biolegend) against the HA epitope. 
 
Flow cytometry.  
Ectopic SERINC expression cassettes were introduced into JurkatTAg S5 -/- 
cells (Usami et al., 2015) by retroviral transduction with 
MSCVpuroSERINC5(iHA) or MSCVpurohS5/hS2-ICL4(iHA). Simultaneously, the 
cells were transduced with the nef-deficient control vector MSCVhygNefSF2FS or 
with MSCVhygNefSF2. After selection with puromycin and hygromycin for one 
week, transduced cell lines grew stably in tissue culture. The doubly transduced 
bulk cultures were surface-stained with anti-HA antibody and APC-conjugated 
anti-mouse IgG (Jackson ImmunoResearch). Samples were then and analyzed 
on a BD LSR II flow cytometer. 
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Analysis of HIV-1 replication in tissue culture.  
Ectopic SERINC expression cassettes were introduced into JurkatTAg S5 -/- 
cells (Usami et al., 2015) by retroviral transduction with MSCVpuroSERINC5 or 
MSCVpurohS5/fS5-ICL4. After selection with puromycin, transduced bulk 
cultures were infected with 2ng ml-1 p24.  
 
Statistical analysis.  
Statistical analysis was performed using a two-tailed unpaired t-test with Welch’s 
correction in case of unequal variance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P 
< 0.0001, NS, not significant (P > 0.05).  
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Chapter III 
The determinants in SERINC5 for its Env-dependent 
antiretroviral activity 
 
 
Abstract 
SERINC5 potently restricts HIV-1 infectivity in the absence of Nef. In 
addition to Nef, some Env glycoproteins derived from neutralizing antibody-
resistant HIV-1 strains antagonize SERINC5’s inhibition of HIV-1 infectivity. 
However, it has remained elusive how SERINC5 inhibits viral infectivity and why 
the inhibition is Env-dependent. To investigate the determinants in SERINC5 that 
govern the inhibition of HIV-1 infectivity, we examined chimeric SERINC proteins 
between SERINC5 and other non-inhibitory SERINCs. We now show that a large 
amino-terminal region of SERINC5 is not specifically required for its antiretroviral 
activity. SERINC5’s inhibitory function, unlike its sensitivity to Nef, requires the 
participation of more than one region. Helix 4, helix 9, and the extracellular loop 5 
(ECL5) of SERINC5 are all required for potent restriction of HIV-1 infectivity. In 
particular, the replacement of the ECL5 of SERINC5 by that of another SERINC 
results in a non-inhibitory SERINC5. The determinates within the ECL5 that 
contribute to the inhibitory activity of SERINC5 are dispersed throughout the 
loop. Furthermore, the ECL5 is a hotspot region that determines the Env-
dependent antiretroviral activity of SERINC5. 
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Introduction 
 
The mechanism by which SERINC5 blocks HIV-1. 
SERINC3 and SERINC5 inhibit the infectivity of Nef-defective viruses 
upon ectopic expression in producer cells (Rosa et al., 2015; Usami et al., 2015). 
We show in Chapter II that the antiretroviral activity is conserved among 
SERINC5 proteins. Furthermore, SERINC5 can target retroviruses other than 
lentiviruses, such as gammaretrovirus MLV (Rosa et al., 2015). However, the 
mechanism by which SERINC5 inhibits viral infectivity is elusive. Studies using 
two different fusion assays suggest that the block mediated by SERINC5 occurs 
at the membrane fusion step (Rosa et al., 2015; Usami et al., 2015). One assay 
is based on the activation of a reporter in the target cells following the delivery of 
Cre recombinase. The other fusion assay is based on the cleavage of a 
fluorescent substrate after the transfer of a chimeric b-lactamase-Vpr (BlaM-Vpr) 
from virions into target cells. Both assays indicate that the incorporation of 
SERINC5 into HIV-1 virions causes a reduction in their ability to fuse with target 
cells (Rosa et al., 2015; Sood et al., 2017; Usami et al., 2015).  
However, it is not clear which stage of viral fusion is blocked by SERINC5. 
The observation that the inhibition of HIV-1 infectivity is more pronounced than 
the inhibition of fusion supports the theory that SERINC5 disrupts the dilation of 
the fusion pore but not pore formation (Rosa et al., 2015; Usami et al., 2015). 
Alternatively, the reason for the discrepancy might be the different sensitivity of 
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assays that measure entry and post-entry events (Foster et al., 2018). A recent 
study provides evidence supporting the notion that SERINC5 inhibits fusion by 
imaging the fusion of single virions virus fusion with living cells (Sood et al., 
2017). Their study suggests that SERINC5 inhibits HIV-cell fusion at the stage of 
small pore formation. They co-labeled the virions with two fluorescent proteins, 
YFP and mCherry. Viral fusion was detected by the release of mCherry-labeled 
Gag through a fusion pore larger than 4 nm in diameter. Fusion of SERINC5-HA 
particles was markedly inhibited compared to that of control virions (Sood et al., 
2017). 
 
Env-dependent antiretroviral activity of SERINC5. 
In addition to Nef, Env glycoproteins play a crucial role in determining 
sensitivity to SERINC5 (Chande et al., 2016; Rosa et al., 2015; Usami et al., 
2015). HIV-1 viruses pseudotyped with vesicular stomatitis virus G protein (VSV-
G) or with the Ebola virus glycoprotein are resistant to SERINC5 (Rosa et al., 
2015). Furthermore, the glycoprotein of the lentivirus EIAV confers partial 
SERINC5 resistance to viral particles, even though the EIAV protein S2 
counteracts SERINC5 in a similar manner as HIV-1 Nef (Chande et al., 2016).  
Virions carrying Env glycoproteins from primary HIV-1 isolates are variably 
affected by SERINC5 (Beitari et al., 2016; Rosa et al., 2015; Usami et al., 2015), 
which explains why the enhancement of infectivity by Nef varies when HIV-1 is 
pseudotyped with Envs derived from primary isolates (Usami and Göttlinger, 
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2013). A panel of transmitted founder viruses are less sensitive to inhibition by 
SERINC5 (Beitari et al., 2016). A study using chimeras between SERINC5-
sensitive and SERINC5-resistant HIV-1 Envs suggests that the V3 stem loop of 
Env is critical for its antagonism of SERINC5 (Beitari et al., 2016). 
To further dissect the block in viral fusion caused by SERINC5, 
researchers examined the effects of fusion inhibitors and neutralizing antibodies 
on SERINC5’s function. I summarized the published studies from two groups in 
Table 1.1 (Beitari et al., 2016; Sood et al., 2017). Beitari et al. evaluated the 
effect of antiretroviral drugs and neutralizing antibodies on the infectivities of 
SERINC5-bearing and -free virions, and Sood et al. used a previously described 
BlaM fusion assay (Miyauchi et al., 2009) to investigate the effects of SERINC5 
on viral fusion  (Table 1.1).  
While there are discrepancies between their observations, both studies 
indicate that SERINC5 disrupts the conformational changes of gp41 induced by 
receptor binding, and possibly the formation of 6HB that drives the fusion 
reaction (Chan et al., 1997; Weissenhorn et al., 1997). Sood et al. show that the 
incorporation of SERINC5 into HIV-1 virions sensitizes viral fusion to neutralizing 
antibodies against gp41, including to anti-MPER antibody 4E10 (Cardoso et al., 
2005; Hessell et al., 2010). Inhibition of HIV-1 infectivity by 4E10 is sensitized by 
SERINC5 incorporation, as suggested by the neutralization assays in the Beitari 
et al. paper (Table 1.1). Furthermore, Sood et al. showed that SERINC5 
sensitizes HIV particles containing both SERINC5-sensitive and SERINC5-
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resistant Envs to T-20, which binds to gp41 and blocks the formation of the 6HB 
(Kilby et al., 1998; Lalezari et al., 2003). However, in Beitari et al. study, 
SERINC5 failed to sensitize SERINC5-resistant NL(AD8V3) to T-20. This 
discrepancy could be due to the fact that AD8V3 is a chimeric Env with an 
exchanged V3 loop, since sensitivity to T-20 is modulated by the V3 loop of 
gp120 (Derdeyn et al., 2000). Another possible reason for the discrepancy is the 
different sensitivities between fusion assay and neutralization assay (Sarzotti-
Kelsoe et al., 2014).  
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SERINC5 incorporation enhances HIV-1 sensitivity to neutralizing antibodies. 
The trimeric HIV-1 Env spike is highly protected from antibody-mediated 
recognition. Nevertheless, broadly neutralizing antibodies target sites of Env 
vulnerability (Kwong et al., 2011). One target site for neutralizing antibodies is the 
initial site of attachment to the CD4 receptor, which is on the outer domain of 
gp120 (Chen et al., 2009; Zhou et al., 2007). The recently isolated antibody 
VRC03 appears to target the CD4 binding site with exceptional affinity, and 
shows neutralization breadths of up to 90% of circulating isolates (Wu et al., 
2010). The human monoclonal antibody PG16, which is also exceptionally potent 
in its neutralizing activity, targets a quaternary epitope formed by the variable 
loops V2 and V3 of gp120 (Burton et al., 2009; Robinson et al., 2010). The 
MPER of gp41 is another target site for neutralizing antibodies because of its 
accessibility during gp41 folding. Human antibodies 2F5, Z13e, and 4E10 can 
recognize the MPER and show reasonable breadths of neutralization, although 
their potency is low (Muster et al., 1993, 1994; Stiegler et al., 2001; Zwick et al., 
2001). 10E8 is a more recently isolated MPER-specific antibody and shows 
higher potency than 4E10 (Huang et al., 2012). Human antibody 35O22 binds to 
a novel site of vulnerability on HIV-1 Env within the interface of gp120/gp41 
(Huang et al., 2014). 
Beitari et al. have shown that SERINC5 sensitizes HIV-1 only to 4E10, 
10E8 and 35O22, which target either the interface of gp120/gp41 or the MPER of 
gp41 (Beitari et al., 2016). On the other hand, none of the tested antibodies 
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targeting the CD4 binding site or the V1/V2/V3 loops inhibited SERINC5-bearing 
HIV-1 to a greater degree than SERINC5-free viruses. SERINC5 incorporation 
also sensitized the HIV-1 fusion to 4E10 in the Sood et al. study (Sood et al., 
2017). Taken together, these studies raise the possibility that SERINC5 blocks 
HIV-1 entry by interfering with the folding of gp41. 
  
Summary  
The mechanism by which SERINC5 potently blocks HIV-1 is not clear, 
though accumulating evidence suggests that the inhibition happens during 
membrane fusion (Rosa et al., 2015; Sood et al., 2017; Usami et al., 2015). 
SERINC5 incorporation sensitizes HIV-1 virions to neutralizing antibodies that 
target the MPER of gp41, which implies that SERINC5 inhibits HIV-1 entry by 
altering the conformation of gp41 (Beitari et al., 2016; Sood et al., 2017). 
SERINC5 incorporation is shown to inactivate Envs that are sensitive to 
SERINC5 (Sood et al., 2017). The stage of entry blocked by SERINC5 would 
further reveal how neutralizing antibody-resistant Envs antagonize SERINC5.  
It is critical to dissect the requirement for each domain in SERINC5 to 
understand how it inhibits HIV-1 infectivity. Among five members in the SERINC 
family, SERINC3 and SERINC5, which are 31.9% identical (ClustalO), possess 
the ability to restrict HIV-1. Though SERINC5 and SERINC2 share 32.4% of 
primary sequence identity (ClustalO), SERINC2 does not inhibit HIV-1 infectivity. 
Interestingly, we find that SERINC2 enhances HIV-1 infectivity to various extents 
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in different producer cell lines. The antiviral activity of SERINC3 and SERINC5 is 
conserved across species (Dai et al., 2018; Heigele et al., 2016; Murrell et al., 
2016). It is particularly important to investigate the determinants in SERINC5 that 
are responsible for its exceptional antiviral potency. 
To this end, we have examined chimeric constructs between SERINC2 
and SERINC5. We conclude that a large amino-terminal portion of SERINC5 is 
not required for its potent inhibitory function. In contrast, the ECL5 of SERINC5 is 
critical for the inhibition of HIV-1 infectivity. By comparing the effects of ECL5 
mutants on virions bearing Envs resistant or sensitive to SERINC5, we report 
that ECL5 is a hotspot region that determines Env sensitivity.  
 
 
 
 
 
 
Results 
 
C13 in the amino terminus of SERINC5 is indispensable for the potent antiviral 
activity of SERINC5.  
Notably, the amino-terminus of SERINC proteins is enriched in cysteines 
(Figure 3.1A). Cysteines at position 12, 14, 19 and 23 of SERINC5 are 
conserved throughout the SERINC protein family. SERINC5 harbors additional 
cysteines compared to other SERINC proteins. According to the putative 
secondary structure of SERINC5 (Schlessinger et al., 2006) and our 
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experimental observations, the amino terminus of SERINC5 is at the cytoplasmic 
side. In the intracellular environment, it is common to find cysteines binding to 
metals and induce conformational changes or enzymatic activities. To examine 
whether enriched cysteines alter SERINC5’s restriction of HIV-1 infectivity, we 
generated C to A point mutations in the amino-terminus of SERINC5 (Figure 
3.1A). C12, C19, and C23 are conserved among SERINC1-5. SERINC5 mutants 
in which these residues were individually change to alanine reduced the 
infectivity of Nef− HIV-1 virions produced in 293T cells to a similar extent (12-fold) 
as wild type SERINC5 (Figure 3.1B). C25 and C26 are conserved among 
SERINCs except for SERINC4, which is absent in Jurkat E6.1 cells at the 
transcriptional level (Usami et al., 2015). Mutations at those sites also did not 
compromise the inhibitory effect of SERINC5 (Figure 3.1B). SERINC5 does not 
share C5, C6, and C13 with other SERINC proteins. While versions of SERINC5 
harboring C5A and C6A mutations reduced HIV-1 infectivity 7.3- and 5.1- fold 
respectively, SERINC5 with a C13A mutation reduced HIV-1 infectivity only 2.8-
fold (Figure 3.1B). We infer that although most of the cysteines in the N terminal 
of SERINC5 are not required for the inhibition of HIV-1 infectivity, C13 is critical 
for the potent inhibitory ability of SERINC5. 
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Figure 3.1. In contrast to other N-proximal cysteines of SERINC5, C13 is 
critical for the potent antiviral activity of SERINC5. 
(A) Alignment of the amino-termini of human SERINC1-5 proteins. Arrows 
indicate cysteine residues that were mutated to alanine. 
(B) Ability of SERINC5 mutants to inhibit the single-round infectivity of Nef- HIV-1 
progeny virions. The histograms represent the mean + SD from three 
measurements. 
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An extensive N-terminal portion of SERINC5 can be replaced without 
compromising antiretroviral activity.     
Since SERINC1 does not restrict HIV-1 infectivity, we used SERINC1 
sequences to replace corresponding regions of SERINC5 in order to examine 
their importance for the inhibition of HIV-1 (Table 3.2). Figure 3.2A illustrates the 
putative structure of SERINC5, and the numbering of the extracellular loops 
(ECLs), helices (Hs) as well as intracellular loops (ICLs). We tested the infectivity 
of Nef-deficient viral particles by visualizing green fluorescent protein (GFP)-
positive cells after exposure to single-cycle Nef- HIV-1-GFP produced in 293T 
cells. Infected TZM-bl indicator cells, which express GFP after infection with HIV-
1, were detected by fluorescence microscopy. The substitution of the first 143 
amino acids (the amino terminus to the third helix) of SERINC5 by the 
corresponding region of SERINC1 had no effect on the anti-HIV activity of 
SERINC5. In contrast, chimeras in which even larger amino-terminal portions of 
SERINC5 were replaced by SERINC1 sequences were unable to inhibit HIV-1 
infectivity (Table 3.2). This was due to either a loss of inhibitory function, or to 
poor expression of the chimeric constructs. We conclude that the region from the 
amino terminus to the third helix is not specifically required for the anti-HIV-1 
effect of SERINC5.   
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Table 3.2. The phenotype of chimeras between SERINC5 and SERINC1. 
 
 
 
 
 
 
 
 
 
 
Chimeras between SERINC2 and SERINC5 reveal the regions critical for 
SERINC5’s inhibitory function. 
SERINC1 is not efficiently incorporated into progeny virions, which may 
have contributed to the loss of restrictive activity by some of the S5/S1 chimeras. 
To circumvent this potential complication, we also used SERINC2 as a parent for 
the construction of chimeras, since higher levels of SERINC2 than that of 
SERINC1 can be detected in progeny HIV-1 virions and since SERINC2 does not 
inhibit HIV-1 infectivity (Figure 3.3A) (Schulte et al., 2018).  
Because the region from the amino terminus to H3 can be replaced 
without affecting SERINC5’s inhibitory function (Table 3.2), we individually 
exchanged loops and helices downstream of this region with corresponding 
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SERINC2 sequences (Table 3.3). The S5/S2(151-179) and S5/S2(180-223) 
chimeras were both expressed in the producer cells and incorporated into 
progeny virions in the absence of NefSF2 (Figure 3.2C), but exhibited distinct 
effects on HIV-1 infectivity (Table 3.3). The S5/S2(151-179) chimera lost the 
ability to inhibit HIV-1 infectivity, suggesting that ECL2 and H4 are critical for 
SERINC5’s inhibitory function. In contrast, the S5/S2(180-223) chimera retained 
the ability to inhibit HIV-1, which suggests that ICL2 and H5 of SERINC5 are 
replaceable without compromising its inhibitory function. The S5/S2(287-342) 
chimera did not inhibit HIV-1 even though it was normally expressed, which 
indicated that the ECL4 and H8 of SERINC5 are required for its inhibitory 
function. 
The S5/S2(1-150) chimera did not exhibit inhibitory function, but was 
neither detected in the producer cells nor in progeny virions, regardless of the 
presence or absence of Nef (Figure 3.2B). The same situation was with 
S5/S2(224-260), S5/S2(261-286), and S5/S2(390-456) chimeras (Table 3.3). 
Thus, these chimeras did not provide information about the importance of the 
replaced regions for the inhibitory function of SERINC5. Besides, the chimeras 
shown in Table 3.3 do not address the importance of the ICL4. None of these 
chimeras were resistant to NefSF2 (Figure 3.2B, C), confirming the importance of 
the ICL4 of human SERINC5 in its responsiveness to Nef, as shown in Chapter 
II. Overall, these findings demonstrated that, unlike the sensitivity of SERINC5 to 
Nef, its inhibitory function of SERINC5 requires more than one region.  
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Figure 3.2. The incorporation of chimeras between SERINC5 and SERINC2.  
(A) Schematic illustration of SERINC5 and the numbering of each domain.  
(B) Western blots showing that S5/S2(1-150) failed to be expressed in the 
producer cells and incorporated into progeny virions.  
(C) Western blots showing the expression and incorporation of S5/S2(151-179) 
and (180-223).  
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Table 3.3. The phenotype of chimeras between SERINC5 and SERINC2. 
 
 
 
 
 
 
 
Helix4 of SERINC5 is required for potent anti-HIV-1 function. 
Helices in SERINC5 determine the overall structure, and thus likely the 
function, of SERINC5. To examine the role of each helix in the inhibitory function 
of SERINC5, we replaced each helix of SERINC5 with its counterpart in 
SERINC2. Chimeras carrying H5 or H8 of SERINC2 inhibited HIV-1 infectivity 
12.0- and 12.5- fold, respectively, which was comparable to the inhibition 
observed with parental SERINC5 (17.8-fold). In contrast, the exchange of other 
helices significantly compromised the inhibitory function of SERINC5 (Figure 
3.3B). To further characterize the requirement for H4, H6, H7, H9, and H10 in 
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SERINC5’s inhibitory function, we examined the effects of increasing the 
amounts of chimeric SERINC5 proteins on HIV-1 infectivity. The S5/S2-H6 and -
H10 chimeras exhibited potent inhibition of HIV-1 infectivity when higher amounts 
of plasmids encoding these constructs were transfected (Figure 3.3C). Thus, 
helices 6 and 10 do not contain essential determinants for the inhibition of HIV-1. 
In contrast, the S5/S2-H4, -H7 and -H9 chimeras exhibited little inhibitory activity 
even when relatively high amounts of plasmids encoding these constructs were 
transfected (Figure 3.3C). The lack of activity of the S5/S2-H7 chimera could be 
attributed to a lack of incorporation into progeny virions (Figure 3.3D). In 
contrast, the S5/S2-H4 chimera was incorporated at a level comparable to that of 
parental SERINC5, and the S5/S2-H9 chimera was incorporated at an even 
higher level (Figure 3.3D). We conclude that helices 4 and 9 are specifically 
required for the anti-HIV-1 activity of SERINC5. (Table 3.3). 
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Figure 3.3. The role of SERINC5’s helices in the restriction of HIV-1 
infectivity. 
(A) SERINC2 enhances the infectivity of Nef- HIV-1 progeny virions.  
(B) The effects of exchanging each helix of SERINC5 on the inhibition of HIV-1 
infectivity. In (A) and (B), the histograms represent the mean + SD from three 
measurements, and the amounts of SERINC plasmids were 100 ng per 
transfection.  
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(C) Not all of the chimeras exhibited potent inhibitory activity when the amounts 
of plasmids used for transfection were increased 10-fold. The lower amount of 
plasmids was 100 ng, and the higher one was 1 µg.  
(D) Western blots showing the incorporation of chimeric SERINC5 proteins into 
Nef- HIV-1 virions.  
 
 
 
 
 
 
 
The ECL5 is critical for the restriction function of SERINC5. 
The observation that SERINC5 exerts more potent inhibition on viral 
infectivity than on HIV-1 fusion suggests that SERINC5 blocks the enlargement 
of the fusion pore (Rosa et al., 2015; Sood et al., 2017; Usami et al., 2015). 
Thus, it is conceivable that ECLs of SERINC5 may disrupt this step of viral 
fusion. Furthermore, ECLs are responsible for the overall structure of SERINC5 
by connecting the helices. To investigate the role of ECLs in the inhibitory 
function of SERINC5, we exchanged each ECL in SERINC5 with the counterpart 
in SERINC2. The exchange of the ECL1 did not compromise the inhibition of Nef- 
HIV-1 infectivity by SERINC5 at all. The chimeric SERINC5 proteins with 
exchanged ECL2 or ECL3 were moderately less potent in inhibiting HIV-1 
(Figure 3.4A). Although the S5/S2-ECL4 chimera was significantly less potent 
than parental SERINC5, it still inhibited the infectivity of Nef- HIV-1 5.3-fold 
(Figure 3.4A). However, SERINC5 bearing the ECL5 of SERINC2 completely 
lost the ability to inhibit HIV-1 infectivity when 100ng expression plasmid was 
used for transfection (Figure 3.4A). The cellular expression level of the S5/S2-
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ECL5 chimera, and its incorporation into progeny virions, were reduced 
compared to parental SERINC5 (Figure 3.4C). However, this is unlikely the 
reason for the loss of restrictive activity, since the S5/S2-ECL5 chimera did not 
result in any inhibition of HIV-1 infectivity even when the amount of expression 
plasmid transfected was increased 10-fold (Figure 3.4B). Overall, we conclude 
that the ECL5 is critical for the ability of SERINC5 to restrict HIV-1 infectivity. 
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Figure 3.4. SERINC5 bearing the ECL5 of SERINC2 fails to inhibit the 
infectivity of Nef- HIV-1 virions. 
(A) Effects of the indicated chimeras on the single cycle infectivity of Nef- HIV-1. 
The amount of SERINC expression plasmid used per transfection was 100 ng. 
The histograms represent the mean + SD from three measurements.  
(B) Transfection of an excess amount of S5/S2-ECL5 does not inhibit HIV-1 
infectivity.  
 117 
(C) Western blots showing the expression and virion-incorporation of the S5/S2-
ECL5 chimera. The amount of SERINC expression plasmid used per transfection 
was 100 ng. 
 
 
 
 
 
 
The ECL5 and H9 of SERINC5 are not sufficient to transfer restriction activity to 
SERINC2. 
The ECL5 and H9 are adjacent to each other. Since both the ECL5 and 
H9 of SERINC5 are important for the inhibition of HIV-1 infectivity, we next tested 
whether the combination of the EL5 and H9, or either of them individually, could 
transfer restriction activity to SERINC2. Thus, we generated chimeric SERINC2 
proteins bearing the ECL5, H9, or both from SERINC5 (Figure 3.5A), and tested 
their effects on HIV-1 infectivity. None of the constructs could suppress the HIV-1 
infectivity, at least at the low amounts of plasmid that were transfected (Figure 
3.5A). The S2/S5-ECL5 and S2/S5-H9 chimeras were both expressed in the 
producer cells, and were incorporated into progeny virions at levels comparable 
to wild-type SERINC2 (Figure 3.5B). When higher amounts of these plasmids 
were transfected, the chimeric SERINC2 proteins slightly enhanced HIV-1 
infectivity, which is similar to the effect of wild type SERINC2 (Figure 3.5A). The 
S2/S5-(ECL5+H9) chimera failed to inhibit HIV-1 infectivity, probably because it 
was not incorporated into progeny virions (Figure 3.5A, B). Together, these 
findings suggest that the ECL5 and H9 of SERINC5 are not sufficient to confer 
inhibitory activity to non-inhibitory SERINC protein. It is possible that the 
 118 
determinants responsible for SERINC5’s restriction function cannot be pinpointed 
to a limited region. 
 A recent study suggested that the region comprising the ECL3, H6, ICL3, 
H7, and the ECL4 of SERINC5 is sufficient to enable SERINC2 to restrict Nef- 
HIV-1 virions (Schulte et al., 2018). To verify their observation in our 
experimental settings, we acquired the relevant plasmids and tested its effect on 
HIV-1 infectivity. Even when a very high amount of the plasmid encoding the 
putative inhibitory chimera (1.5 µg) was transfected, the chimeric SERINC2 
merely reduced HIV-1 infectivity 1.3-fold (Figure 3.5C). In addition, the CMV-
based construct led to higher SERINC expression levels than the pBJ5-based 
SERINC expression plasmids used by us. Thus, we were unable to confirm that 
the region extending from ECL3 to ECL4 of SERINC5 is sufficient to transfer 
inhibitory activity to SERINC2.   
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Figure 3.5. Chimeric SERINC2 proteins fail to inhibit HIV-1 infectivity.  
(A) Schematic illustration of the S2/S5-ECL5, -H9 and -(ECL5+H9) chimeras, and 
their effects on Nef- HIV-1 progeny virions. The amounts of transfected plasmids 
were 100 ng and 1.0 µg. The red numbers indicate the exchanged regions.  
(B) Western blots showing the cellular expression and viral incorporation of 
chimeric SERINC2 proteins in the absence of Nef. 
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(C) Schematic illustration of the S2/S5-(ECL3--ECL4) chimera (left). The red 
numbers indicate the exchanged regions. The S2/S5-(ECL3--ECL4) chimera fails 
to inhibit HIV-1 infectivity (right).  
In all cases, the histograms represent the mean + SD from three measurements. 
 
 
 
 
 
 
The inhibitory determinants within the ECL5 are dispersed throughout the loop.  
Given that the ECL5 of SERINC2 is three amino acids shorter than that of 
SERINC5, we hypothesized that the length of the ECL5 is one of the factors 
determining the antiretroviral function of SERINC5. To test this hypothesis, we 
inserted consecutive 3-amino-acid-deletions into the ECL5 of SERINC5 (Figure 
3.6A). In addition, if the hypothesis were disproved, these deletions were 
expected to allow us to narrow down relevant determinants within the ECL5. 
None of the deletions had the same effect as the replacement of the whole ECL5 
(Figure 3.4A and Figure 3.6B). Each of the deletion mutants retained restrictive 
activity, reducing  HIV-1 infectivity 3.3- to 7.9-fold, compared to the 30.0-fold 
inhibition obtained with parental SERINC5 (Figure 3.6B). The deletions within 
the ECL5 did not affect the levels of expression of SERINC5, or its incorporation 
into progeny virions (Figure 3.6C). We conclude that the importance of the ECL5 
for SERINC5’s antiretroviral activity is not merely due to its length. Furthermore, 
determinants important for the restrictive activity of SERINC5 are dispersed 
throughout the ECL5.  
 
 121 
 
 
 
 
Figure 3.6. Deletions within the ECL5 of SERINC5 only partially impaired  
its ability to restrict HIV-1 infectivity. 
(A) Alignment of the ECL5 regions of human SERINC1-5, and of SERINC5 
proteins from other species (frog and zebrafish) that possess the antiretroviral 
activity. The ECL5 deletions examined are also indicated.     
(B) ECL5 deletions impair the ability of SERINC5 to inhibit the infectivity of Nef- 
HIV-1 virions. The histograms represent the mean + SD from three 
measurements. 
(C) Western blots showing that a SERINC5 mutant with a deletion in the ECL5 is 
normally expressed and incorporated into progeny virions. 
  
 122 
The ECL5 determines the Env-dependent antiretroviral activity of SERINC5. 
In the experiments described above, the Env expressed in trans for 
measuring single-round infectivity was derived from HIVHXB2, a laboratory-
adapted X4-tropic strain. Previous studies from several groups had suggested 
that some of the primary R5-tropic Envs, such as EnvJRFL, can partially overcome 
SERINC5 inhibition (Beitari et al., 2016; Rosa et al., 2015; Usami et al., 2015). 
To define the role of the ECL5 of SERINC5 in its antagonism by Env, we 
examined the effects of deletions within the ECL5 on the infectivity of virions 
carrying EnvJRFL. SERINC5 mutants with deletions in the ECL5 did not inhibit viral 
infectivity, while parental SERINC5 reduced the infectivity 4.2-fold (Figure 3.7A). 
Paradoxically, the S5-ECL5D3 mutant slightly enhanced the infectivity of progeny 
virions carrying EnvJRFL (Figure 3.7A).  
When comparing the specific infectivity of virions incorporating SERINC5 
and either EnvJRFL or EnvHXB2, we noticed that SERINC5’s inhibition of virus 
bearing EnvHXB2 is 7.4-fold stronger compared to the inhibition of virus bearing 
EnvJRFL (Figure 3.7B). Notably, each SERINC5 deletion mutant inhibited the 
infectivity of progeny virions carrying EnvJRFL to a 4.0- to 8.1-fold lesser extent 
than the infectivity of virions carrying EnvHXB2 (Figure 3.7B). In contrast, the 
S5/S2-ECL5 chimera, which has the whole ECL5 replaced, moderately inhibited 
the infectivity of virions carrying EnvJRFL, but not the infectivity of virions carrying 
Env HXB2 (Figure 3.7A and 3.4A). It suggested that ECL5 mutations 
proportionally disrupts the antagonism of SERINC5 by Env. However, the 
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exchange of the ECL5 loop led to the discordant antagonism of SERINC5. Taken 
together, we conclude that the ECL5 is a hotspot region that determines the Env-
dependent antiretroviral activity of SERINC5.  
 
 
 
 
 
 
 
Figure 3.7. ECL5 mutations proportionally disrupts the antagonism of 
SERINC5 by Env. 
(A) Effects of deletions within in the ECL5 of SERINC5 on its ability to inhibit the 
infectivity of Nef- HIV-1 virions carrying EnvJRFL. 100 ng plasmids expressing 
SERINC5 mutants were used per transfection.  
(B) Fold change indicates the ratio of the relative infectivity of virions carrying 
EnvJRFL to EnvHXB2, when 100 ng plasmids expressing corresponding SERINC 
mutants were co-transfected. 
In all cases, the histograms represent the mean + SD from three measurements. 
  
NS 
Env: JRFL 
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Discussion  
 
Our results indicate that the ECL5 of SERINC5 is crucial its ability to 
inhibit HIV-1 infectivity. Even at the highest amount of transfected expression 
plasmids, SERINC5 bearing the ECL5 from SERINC2 did not inhibit HIV-1 
infectivity (Figure 3.4A). In addition, our results indicate that helices H4 and H9 
of SERINC5 both play an important role in maintaining the full potency of 
inhibition. However, the ECL5 and H9 of SERINC5 together failed to transfer the 
ability to restrict HIV-1 to SERINC2 (Figure 3.5A). Determinants throughout the 
ECL5 contribute to the restriction of HIV-1 by SERINC5,since all of the deletions 
within the ECL5 resulted in a partial reduction in the ability of SERINC5 to inhibit 
HIV-1 infectivity (Figure 3.6B). Interestingly, the replacement of the ECL5 of 
SERINC5 by that of SERINC2 eliminated the ability to inhibit the infectivity 
conferred by EnvHXB2 but not by EnvJRFL, even though EnvJRFL is far less affected 
by wild type SERINC5 (Figure 3.7B). Taken together, our findings suggest that 
the ECL5 determines the Env-specific antiretroviral activity of SERINC5. 
 
The determinants of SERINC5 that governs the restriction. 
 
Schulte et al. suggested that the transfer of an over 100-amino acid region 
from SERINC5 that begins with the ECL3 and ends with the ECL4 was sufficient 
to render SERINC2 capable of restricting HIV-1 infectivity (Schulte et al., 2018). 
We acquired the relevant expression plasmids from this group and tested it in our 
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experimental setting. Even at the highest amount of transfected plasmid, we only 
observed a slight reduction of viral infectivity (Figure 3.5C). The clone they used 
is codon-optimized and in a CMV-driven vector. Thus, the SERINC5 expression 
level of their plasmids is much higher than the pBJ5-based constructs used in our 
study. The failure of the chimeric SERINC2 to inhibit HIV-1 infectivity despite high 
expression levels suggests that the determinants of SERINC5’s restriction 
function are unlikely to be in ECL3, the ECL4, or the sequences that connect 
these elements.  
We have shown that most of this region, which consists of the ECL3, H6, 
the ICL3, H7, and the ECL4, is also dispensable for the potent inhibition of HIV-1 
infectivity by SERINC5. With merely 100 ng of a weak expression plasmid 
transfected, SERINC5 bearing the ECL3 or ECL4 of SERINC2 inhibited HIV-1 
infectivity 12.0- and 5.3-fold, respectively (Figure 3.4A). 1 µg of the S5/S2-H6 
chimera inhibited HIV-1 infectivity as potently as parental SERINC5 (Figure 
3.4C). Though the S5/S2-H7 chimera was not as potently as SERINC5 bearing 
H6 of SERINC2, it caused a 3-fold reduction in HIV-1 infectivity (Figure 3.4C). 
These observations are in agreement with our observation that the ECL3-H6-
ICL3-H7-ECL4 portion of SERINC5 is not sufficient to confer the ability to restrict 
HIV-1 to a non-inhibitory SERINC. 
At the highest amount of plasmids transfected, the S2/S5-ECL5 chimera 
was 1.6-fold less effective than wild type SERINC2 in increasing HIV-1 infectivity. 
However, the ECL5 of SERINC5 failed to render SERINC2 restrictive for HIV-1 
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infectivity (Figure 3.5A). SERINC2 bearing both the ECL5 and the adjacent H9 
helix from SERINC5 also did not acquire the ability to restrict HIV-1, possibly 
because it was poorly incorporated into progeny virions (Figure 3.5B). One 
possible reason for the failure to confer inhibition in the context of SERINC2 
could be that the determinants responsible for the enhancement HIV-1 infectivity 
by SERINC2 are unrelated to those that govern the inhibitory effects of 
SERINC5. 
 
The impact of SERINC5 on conformational changes in Env. 
The effects of SERINC5 incorporation on neutralization sensitivity 
suggests that SERINC5 inhibits HIV-1 infectivity by altering the conformation of 
Env (Beitari et al., 2016; Sood et al., 2017). In this study, we show that the ECL5 
of SERINC5 is essential for its inhibition of HIV-1. It is tempting to speculate that 
this extracellular loop in SERINC5 interferes with conformational changes of Env.  
The V3 stem loop of HIV-1 Env has been shown to determine its 
antagonism of SERINC5 (Beitari et al., 2016). A previous study suggests that the 
effects of Nef on HIV-1 infectivity are determined by the conformational status of 
the apex of the Env trimer (Usami and Göttlinger, 2013). Cryo-EM structures 
reveal that the V1, V2 and V3 variable regions are near the apex of the Env 
trimer (Liu et al., 2008; White et al., 2010), which acts to stabilize the unliganded 
Env spike (Mao et al., 2012). I hypothesize that the ECL5 determines the 
sensitivity of Env to SERINC5 by altering the Env trimer. An experimental 
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strategy to examine this hypothesis is to compare EnvSF162, an R5-tropic Env 
sensitive to SERINC5’s restriction, with the SERINC5-resistant EnvJRFL, and how 
the SERINC5-sensitivity changes when the V1, V2, and V3 of EnvSF162 and 
EnvJRFL are exchanged. EnvJRFL becomes considerably more neutralization 
sensitive upon replacement of its V1/V2 region by that of neutralization-sensitive 
EnvSF162 (Pinter et al., 2004). If the proposed model upholds, the extent of 
inhibition of HIV-1 infectivity by SERINC5 mutants with deletions in the ECL5 of 
would be switched by exchanging the variable regions of EnvSF162 and EnvJRFL. In 
contrast, the effects of the S5/S2-ECL5 chimera would not be swapped when the 
variable regions of Envs were exchanged. Another experiment to test the 
hypothesis is to examine the effects of the linear peptide of ECL5 on the 
conformational changes of Env. However, it is worth noticing that peptide binding 
assays can suggest off-pathway structures corresponding to an inactivated gp41 
in addition to conformations leading to viral fusion (Melikyan, 2008).  
 
The antagonism of SERINC5 by Env. 
The sensitivity of Env to SERINC5 might be related the number of Env 
trimers required for entry (Brandenberg et al., 2015). Whether SERINC5 
incorporation interferes with Env incorporation is controversial (Sood et al., 2017; 
Usami et al., 2015), as is the effect of Nef on the incorporation of Env. Some 
studies reported an enhancement of Env incorporation by Nef (Day et al., 2004; 
Schiavoni et al., 2004), while no effect on Env incorporation was observed in 
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other studies (Miller et al., 1995; Pizzato et al., 2007; Usami and Göttlinger, 
2013).  
Neutralizing antibody-resistant EnvJRFL can overcome SERINC5 inhibition 
independent of Nef (Rosa et al., 2015; Usami et al., 2015). Why did both HIV and 
EIAV evolve redundant mechanisms to bypass inhibition by SERINC5 in addition 
to the counteraction by viral proteins (Chande et al., 2016; Usami et al., 2015)? 
Similarly, HIV-1 Vpu and Nef also have evolved complementary abilities to 
remove the HIV-1 receptor CD4 from the cell surface (Lindwasser et al., 2007). It 
is possible that SERINC5 performs additional functions that restrict virus 
replication but are not counteracted by Nef (Chande et al., 2016).   
 The cellular site of viral fusion matters for the antiviral activity of host 
factors. The glycoproteins of VSV, Ebola and EIAV can overcome the restriction 
by SERINC5 (Chande et al., 2016; Rosa et al., 2015), which suggests that the 
use of an endosomal entry pathway can reduce sensitivity to SERINC5 (Chande 
et al., 2016; Jin et al., 2005). Similarly, the antiviral restriction activity of the 
interferon induced transmembrane (IFITM) protein family is linked to the cellular 
site of viral fusion (Foster et al., 2018). The IFITM proteins, including IFITM1, 
IFITM2, and IFITM3, have been demonstrated to inhibit HIV-1 replication by 
blocking virus entry (Li et al., 2013; Lu et al., 2011), however, to a lesser degree 
compared to their effects on other viruses (Diamond and Farzan, 2013; Foster et 
al., 2018). IFITM1 is primarily localized at the plasma membrane, while IFITMs 2 
and 3 are within endosomal compartments. Virions that utilize CCR5 for entry are 
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more susceptible to inhibition by IFITM1, and CXCR4-using virions were more 
subject to restriction by IFITMs 2 and 3 (Foster et al., 2018). 
 
How does SERINC5 possibly affect HIV-1 pathogenesis? 
The term “transmitted founder virus” refers to the inferred consensus 
sequence of a viral isolate during acute infection of humans or monkeys that is 
responsible for establishing productive clinical infection (Keele et al., 2008; Lee 
et al., 2009). The sensitivity of Envs from various primary isolates to neutralizing 
antibodies varies. Envs from newly transmitted viruses are sensitive to antibodies 
from the partner (Derdeyn et al., 2004). Based on the sensitivity to antibody-
mediated neutralization, HIV-1 primary isolates are divided into four 
subgroups: with very high sensitivity (Tier 1A), above-average sensitivity (Tier 
1B), moderate sensitivity (Tier 2), or low sensitivity (Tier 3) (Li et al., 2005; 
Seaman et al., 2010). The neutralization sensitivity of transmitted founder viruses 
follows the similar pattern with tier 2 or 3 primary virus strains (Li et al., 2005), 
whose V3 and coreceptor binding surface regions are occluded from binding by 
neutralizing monoclonal or polyclonal HIV-1 antibodies (Keele et al., 2008). 
Transmitted founder viruses are relatively insensitive to inhibition by 
SERINC5 (Beitari et al., 2016). In this study, we show that R5-tropic 
neutralization-resistant EnvJRFL is more resistant to SERINC5 inhibition 
compared to the lab adapted strain EnvHXB2 (Figure 3.6), which is in agreement 
with previous studies (Beitari et al., 2016; Rosa et al., 2015; Usami et al., 2015). 
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It is possible that SERINC5 exerts pressure on Env selection during the primary 
infection or viral persistence. Thus, it is important to further investigate the 
relationship between SERINC5 expression levels and the evolution of env during 
the course of disease progression. 
 
 
Materials and methods 
 
Cells.  
293T cells were gifts from G. Crabtree, D. Baltimore. TZM-bl cells were obtained 
from the AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH.  
 
Analysis of virus infectivity.  
Pseudovirions capable of a single round of replication were produced by 
transfecting 293T cells using a calcium phosphate precipitation method. The cells 
were co-transfected with 2 µg HXB/Env−/Nef−, 0.4 µg pSVIIIenv-based plasmid 
expressing EnvHXB2 or, where indicated, EnvJRFL, and the indicated amounts of 
pBJ5-based plasmids expressing wild type or chimeric SERINC5 proteins, or with 
equimolar amounts of empty vector. In addition, equal amounts of the nef-
deficient pNefFS or of 0.5 µg plasmid expressing an HIV-1 Nef were co-
transfected where indicated. Supernatants containing progeny virions were 
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harvested one day post transfection, clarified by low-speed centrifugation, filtered 
through 0.45 μm pore filters, and then used immediately to infect TZM-bl 
indicator cells in triplicate in 6-well plates. Aliquots of the virus stocks were frozen 
for HIV-1 capsid (p24) antigen quantitation by a standard ELISA. Three days post 
infection, the indicator cells were lysed, and β-galactosidase activity induced as a 
consequence of infection was measured using a kit (E2000; Promega). Values 
were normalized for the amount of p24 antigen present in the supernatants used 
for infection.  
Alternatively, the HIV-1 vector HIVec2.GFP was co-transfected together 
with HXB/Env−/Nef−, the Env expression plasmid and a pBJ5-based plasmid 
expressing wild type or chimeric SERINC5 proteins. After exposure to equal 
amounts of virus, infected TZM-bl cells were then identified based on GFP 
expression. 
 
Analysis of SERINC incorporation.  
293T cells were co-transfected with 1 µg HXB/Env−/Nef−, pBJ5-based expression 
plasmids for C-terminally HA-tagged SERINCs or SERINC chimeras (0.1 µg, 
unless indicated otherwise), and 0.5 µg  nef-deficient control plasmid pNefFS or a 
plasmid expressing an HIV-1 Nef. Virions released into the medium were pelleted 
through 20% sucrose cushions, and virus- and cell-associated proteins were 
detected by western blotting as described (Accola et al., 2000). Since SERINC 
proteins are highly aggregation-prone (Usami et al., 2015), samples used for the 
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detection of SERINCs were not boiled before loading. The antibodies used were 
183-H12-5C against HIV-1 CA, and HA.11 (Biolegend) against the HA epitope.  
 
Expression plasmids.  
The env- and nef-deficient HIV-1 provirus HXB/Env−/Nef−, the pSVIIIenv-based 
plasmids expressing EnvHXB2 or EnvJRFL, the pBJ5-based expression plasmids for 
the Nef proteins of HIV-1SF2, the nef-deficient control plasmid pNefFS, and the 
pBJ5-based expression plasmid for human SERINC2, human SERINC2-HA, 
human SERINC5, and human SERINC5-HA have been described (Dorfman et 
al., 2002; Helseth et al., 1990; Pizzato et al., 2007; Usami et al., 2015). The 
plasmids for S2/S5-(ECL3--ECL4), S2 and S5 in Figure 3.5C were provided by 
F. Diaz-Griffer, and was described (Schulte et al., 2018). DNAs encoding mutant 
and chimeric proteins without or with C-terminal HA tags were generated using 
an overlap extension PCR method (Horton et al., 1989) and inserted into pBJ5 
downstream of a Kozak sequence. Point mutations in Figure 3.1 were generated 
using Pfu DNA polymerase (Agilent) via site-directed mutagenesis. For chimeras 
in Table 3.2, the numbers following S1 indicate the residues of SERINC1 
replaced by the counterpart of SERINC5. The residues for the counterpart of 
SERINC5 were listed in Table 3.4. Table 3.5 listed the primary sequences of the 
chimeric constructs in Table 3.3. Table 3.6 listed the primary sequences of the 
constructs in Figure 3.3 and 3.4. Table 3.7 listed the primary sequences of the 
constructs in Figure 3.5.  
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 Table 3.4. The primary sequences of chimeras of SERINC5 and SERINC1. 
 
 
 
 
 
 
Table 3.5. The primary sequences of chimeras of SERINC5 and SERINC2. 
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Table 3.6. The primary sequences of chimeric SERINC5 proteins with 
exchanged helices and ECLs of SERINC2. 
 
 
 
 
 
Table 3.7. The primary sequences of chimeric SERINC2 proteins. 
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Statistical analysis.  
Statistical analysis was performed using a two-tailed unpaired t-test with Welch’s 
correction in case of unequal variance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P 
< 0.0001, NS, not significant (P > 0.05). 
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Chapter IV 
Discussion 
 
 
The multipass transmembrane protein SERINC5 is a newly defined 
antiretroviral host factor. SERINC5 potently inhibits HIV-1 infectivity, and can be 
counteracted by the HIV-1 accessory protein Nef (Rosa et al., 2015; Usami et al., 
2015). However, the counteraction of SERINC5 by Nef and the mechanism by 
which SERINC5 blocks HIV-1 are poorly understood. The work presented in this 
dissertation for the first time describes the role of SERINC5 subdomains in the 
interplay between Nef and the inhibition of HIV-1 by SERINC5.  
 
Counteraction of SERINC5 by Nef. 
In agreement with other studies (Heigele et al., 2016; Murrell et al., 2016), 
we observed that the antiretroviral activity is conserved among mammalian 
SERINC5 proteins. In Chapter II, we demonstrate that mouse SERINC5 is as 
potent as human SERINC5 in inhibiting HIV-1. A previous analysis of mouse and 
five primate SERINC5 orthologs showed that all potently inhibited  SIV and HIV-1 
(Heigele et al., 2016). We have extended these observations by showing that the 
SERINC5 proteins of zebrafish and frog also possess potent antiretroviral 
activity. A computational analysis shows that primary sequences of SERINC5 
proteins from various species are highly conserved (Murrell et al., 2016). Unlike 
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the majority of host restriction factors, SERINC5 orthologs do not display the 
signatures of an evolutionary arms race with viral pathogens. SERINC5 is not 
interferon-inducible (Usami et al., 2015), which is another trait that separates 
SERINC5 from a typical restriction factor.  
 We demonstrate that SERINC5’s responsiveness to Nef is divergent, 
though its antiretroviral activity is conserved. HIV-1 Nef does not counteract the 
inhibitory effects of frog or zebrafish SERINC5. It has been shown in a previous 
study that the counteraction of various primate SERINC5 proteins by Nef is 
largely species-independent (Heigele et al., 2016). Thus, SERINC5 probably 
poses no major obstacle for zoonotic transmission of primate lentiviruses . 
The results presented in Chapter II demonstrate that the longest 
intracellular loop ICL4 of SERINC5 governs its responsiveness to Nef. This 
conclusion is supported by several key findings: (1) transfer of the ICL4 of human 
SERINC5 is sufficient to confer Nef responsiveness to frog SERINC5; (2) the 
ICL4 of human SERINC5 confers sensitivity to widely divergent Nefs, including 
Nefs from various HIV-1 strains and several SIV Nefs; (3) though parental human 
SERINC3 is resistant to downregulation by NefSF2, it acquires sensitivity to NefSF2 
in the presence of the ICL4 of human SERINC5; (4) the ICL4 of frog SERINC5 
confers resistance to both clade B and clade C Nefs; (5) the ICL4 of human 
SERINC2 confers resistance to NefSF2. In sum, these data demonstrate that Nef 
responsiveness can be transferred by exchanging the ICL4 of SERINC proteins.   
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While our observations clearly show that the ICL4 of SERINC5 governs 
Nef responsiveness, additional studies are desired to understand whether Nef 
directly binds to SERINC5. We examined the virion incorporation of LL164,165AA 
AP-2 binding site mutant of NefLAI, which does not counteract SERINC5 (Rosa et 
al., 2015). The mutant Nef is more abundant in HIV-1 virions produced in the 
presence of the fS5/hS5-ICL4 chimera rather than of frog SERINC5. This 
provides indirect evidence suggesting a physical interactions of SERINC5 with 
Nef.  
Nef has been shown to bind to the CD4 cytoplasmic tail using yeast two-
hybrid assays and purified proteins (Cluet et al., 2005; Harris and Neil, 1994; Jin 
et al., 2004; Preusser et al., 2001; Ross et al., 1999). Furthermore, HLA-A has 
been co-immunoprecipitated with Nef (Roeth et al., 2004). Also, Nef has been 
found to form a complex with MHC-I molecules in the endoplasmic reticulum 
(Kasper et al., 2005). A recent study shows that Nef binds to SERINC5 in living 
cells using a bimolecular fluorescence complementation assay (Shi et al., 2018). 
Yeast two-hybrid assays and assays based on purified proteins can be applied to 
test the binding of the ICL4 of SERINC5 to Nef as well. However, unlike CD4 and 
MHC-I, SERINC5 is a multipass transmembrane protein. The ICL4 likely forms a 
higher-order structure with other intracellular loops or helices. Thus, it may not be 
informative to examine the binding of Nef to SERINC5 using only a linear 
polypeptide of ICL4.  
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Furthermore, an analysis of complexes containing SERINC proteins 
bearing distinct ICL4 loops may reveal novel cellular machinery involved in the 
regulation of SERINC5. However, it may be challenging to perform co-
immunoprecipitation studies with SERINC5 given that (1) it is a large 
hydrophobic protein prone to aggregation and (2) a specific antibody for 
SERINC5 is lacking.  
We report that the ICL4 of human SERINC5 confers sensitivity to widely 
divergent Nefs, including SIVmac239, SIVagm155, and SIVagm677. The 
endocytic ExxxLL motif is conserved among these SIV Nefs, and mutations of 
the dileucine within the motif to AA has been shown to disrupt the ability of Nef to 
counteract SERINC5 (Heigele et al., 2016). The same study, however, reported 
that the efficiency with which different SIV Nefs counteract SERINC5 varies 
considerably. Furthermore, the extent of Nef-mediated SERINC5 antagonism 
correlates with the prevalence of different SIVs in their respective natural hosts, 
which suggests a role for SERINC5 in viral spreading in vivo.  
The effects of Nef polymorphisms on SERINC5 antagonism have not been 
thoroughly investigated. Nef plays a key role in promoting disease progression 
and viral pathogenesis, but which Nef activities are crucial for viral replication and 
pathogenesis in vivo is far from clear (reviewed in Kirchhoff, 2010). Thus, it may 
be rewarding to investigate the counteraction of SERINC5 by Nefs from elite 
controllers and chronic progressors. Relatively inefficient SERINC5 antagonism 
may contribute to the mechanism of the spontaneous control of HIV-1. 
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Unknown functions of SERINC proteins 
Nef selectively downregulates some surface proteins but leaves others 
from the same family unaffected. For instance, Nef downregulates HLA-A and -B 
molecules from the cell surface, which prevents CTL responses towards the 
infected cells. On the other hand, Nef does not redirect the cellular trafficking of 
HLA-C or -E molecules to avoid the killing of infected cells by NK cells (Cohen et 
al., 1999; Le Gall et al., 1998). However, the downregulation of HLA-C by Vpu in 
primary HIV-1 clones suggests new roles of CTLs and NK cells in HIV-1 infection 
(Apps et al., 2016). 
Similarly, Nef selectively downregulates some of the SERINC proteins 
from the cell surface but leaves others unaffected (Matheson et al., 2015; Rosa 
et al., 2015; Usami et al., 2015). Experiments described in Chapter III surprisingly 
revealed that SERINC2 significantly enhances the infectivity of HIV-1 progeny 
virions. Thus, leaving SERINC2 on the cell surface could be beneficial for the 
virus. Further studies are needed to determine the physiological functions not 
only of SERINC3 and SERINC5, but of other SERINC proteins as well. Their 
resistance to Nef counteraction might reveal a novel mechanism of immune 
evasion by HIV-1. Possible questions to be addressed include (1) whether 
SERINC proteins engage/activate/inactivate immune receptors; (2) whether the 
surface expression levels of SERINC proteins alter the recognition of infected 
cells; (3) how each of the SERINC proteins impacts HIV-1 infectivity in different 
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cell subsets, under distinct conditions; (4) what the cell surface density of each 
SERINC protein is in different T cell subsets is.  
Importantly, our findings in Chapter II suggest that SERINC2 is resistant to 
NefSF2 but not to Nef97ZA012. We further show that both SERINC2 and the 
hS5/hS2-ICL4 chimera respond to Nef97ZA012. Thus, it is possible that Nef97ZA012 
recognizes determinants within the ICL4 of SERINC2. We also show that point 
mutations of SERINC5 at L350 and I353 cause a loss of responsiveness to 
NefSF2. The ICL4 regions of SERINC5 and SERINC2 are poorly aligned given the 
low similarities. The ICL4 loop of SERINC2 is 12-amino acid shorter than that of 
SERINC5. Residues corresponding to L350 or I353 of SERINC5 are not present 
in the SERINC2 ICL4. The determinants within the ICL4 of SERIN2 that are 
responsible for its responsiveness to Nef97ZA012 have not been investigated. 
Based on our findings concerning the ICL4 of SERINC5, L361 and A363 of 
SERINC2 are potential candidates.   
In summary, Chapter II demonstrates that the antiretroviral activity of 
SERINC5 proteins is conserved among different vertebrate species. However, 
their responsiveness to Nef is divergent. The ICL4 region of SERINC5 governs 
its counteraction by Nef. The ICL4 region of human SERINC5 can transfer the 
responsiveness to widely divergent Nefs. We also show evidence for a potential 
physical interaction of SERINC5 with Nef. Thus, our studies provide valuable 
insights into how HIV-1 Nef evades the intrinsic immunity that would otherwise 
potently restrict viral infectivity.  
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Conditional inhibition of HIV-1 by SERINC5 
 In Chapter III, we aimed to investigate the determinants of SERINC5 that 
govern its inhibition of HIV-1. We examined the role of each helix and 
extracellular loop of SERINC5 in the inhibition of HIV-1 by exchanging them with 
their counterparts in SERINC2. We show that more than one domain is required 
for potent inhibition of HIV-1 infectivity. We provide evidence that the exchange 
of the ECL5 causes a complete loss of function of SERINC5. Furthermore, our 
results suggest that the ECL5 is a hotspot region carrying out the Env-dependent 
antiretroviral activity of SERINC5. 
 The mechanism by which SERINC5 inhibits HIV-1 is far from clear. To 
investigate which region of SERINC5 is crucial, we generate chimeric SERINC 
proteins between SERINC5 and other SERINC proteins that do not exhibit 
antiretroviral activity. We thoroughly examine the requirements for each helix and 
extracellular loop for the inhibition of HIV-1, and the results are now summarized 
in Figure 4.1. Our data clearly demonstrate the importance of the ECL5 for the 
inhibition of HIV-1. SERINC5 bearing the ECL5 of SERINC2 completely lost its 
effect on HIV-1 infectivity, even when an excessive amount was ectopically 
expressed. A similar requirement was not seen for any other individual ECL or 
helix. The exchange of the ECL2 together with helix H4, or of helices H4 or H9, 
caused a partial loss of SERINC5’s inhibitory function. Other loops and helices 
were replaceable with no or only a moderate loss of function. Our results also 
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indicate that more than one domain of SERINC5 is needed to confer inhibitory 
function to a non-inhibitory SERINC protein like SERINC2.  
 
 
 
 
 
 
 
 
 
Figure 4.1. The significance of each domain of SERINC5 in the inhibition of 
HIV-1.  
The numbers in grey indicate the domains not absolutely required for the fully 
potent inhibition of HIV-1. The domains numbered in yellow are critical for 
SERINC5’s function. The domains highlighted in red indicate the significance 
evidenced by several constructs. The numbers in black indicate domains whose 
role could not be determined in this study due to the abnormal expression of the 
resulting constructs. 
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Though we have shown that the ECL5 of SERINC5 is critical for the 
inhibition of HIV-1, further studies are needed to determine whether the 
mechanism is dependent on the primary sequence or configuration of the ECL5. 
For example, the antiviral activity of tetherin is dependent on the configuration 
rather than the primary sequence (Perez-Caballero et al., 2009). A completely 
artificial protein, lacking sequence homology with native tetherin, can mimic its 
antiviral activity. This finding reveals that tetherin functions autonomously and 
restricts viral release via its two membrane anchors (Foster et al., 2018; Malim 
and Bieniasz, 2012; Perez-Caballero et al., 2009).  
Here we show that each of the SERINC5 mutants with deletions within the 
ECL5 reduces HIV-1 infectivity 3.3- to 7.9-fold, whereas the S5/S2-ECL5 chimera 
exhibited no inhibitory activity at all. Together, these findings suggest that the 
determinants in the ECL5 involved in HIV-1 inhibition are dispersed throughout 
the loop. An alternative explanation is that the conformation of SERINC5 is more 
important for the antiviral activity of SERINC5 than its primary sequence. 
Possible future experiments to address this possibility include the replacement of  
the ECL5 with artificial peptides with predicted similar structure but lacking 
sequence homology with the native loop of SERINC5. Such artificial proteins 
might reveal the mechanism by which SERINC5 inhibits HIV-1. 
Furthermore, in agreement with previous studies (Beitari et al., 2016; 
Rosa et al., 2015; Usami et al., 2015), we also find that Env glycoproteins can 
antagonize the antiretroviral activity of SERINC5. SERINC5’s inhibition of viruses 
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bearing EnvHXB2 is 7.4-fold stronger than the inhibition of viruses bearing EnvJRFL. 
By comparing the effects of the deletions within the ECL5 of SERINC5 on virions 
bearing EnvHXB2 with ones bearing EnvJRFL, we show that ECL5 deletions 
proportionally disrupts the antagonism of SERINC5 by Env. However, the 
exchange of the whole loop led to the discordant antagonism of SERINC5, which 
suggests that the ECL5 is a hotspot region carrying out the Env-dependent 
antiretroviral activity of SERINC5.  
A previous study suggests that the V3 loop of Env determines the ability of 
HIV-1 Env to counter SERINC5 (Beitari et al., 2016). NL4-3 Env bearing the V3 
loop of SERINC5-resistant Envs becomes resistant to ectopic SERINC5 (Beitari 
et al., 2016). To examine the role of the ECL5 in SERINC5 antagonism by Env, 
future studies can test the effects of the deletions within the ECL5 on virions 
bearing wild type EnvNL4-3 or NL4-3 Env bearing the V3 loop from EnvJRFL.  
In sum, our study in Chapter III addresses the importance of each domain 
of SERINC5 in the inhibition of HIV-1 (Figure 4.1). SERINC5 bearing the ECL5 
of SERINC2 completely loses its antiviral activity. Moreover, the impaired 
function cannot be compensated by excessive expression levels. We further 
show that the ECL5 is a hotspot region carrying out the Env-dependent 
antiretroviral activity of SERINC5. These results underscore the importance of 
the ECL5 in the antiviral activity of SERINC5.  
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Conclusions 
 
 In summary, the work presented in this dissertation advances our 
understanding of the novel antiviral factor SERINC5 and its antagonism by Nef 
and Env. The work provides key mechanistic details that support a model in 
which the sensitivity of SERINC5 proteins to HIV-1 Nef is not conserved and Nef 
responsiveness can be transferred by exchanging the fourth intracellular loop of 
SERINC5. This information represents a critical improvement in our 
understanding of the intrinsic antiviral factor SERINC5, and for the first time 
demonstrates that human SERINC5 can be modified to restrict HIV-1 even in the 
presence of Nef. This work also reveals a critical role for the fifth extracellular 
loop in the antiviral activity of SERINC5, and raises several important new 
mechanistic questions. Overall, this work provides a framework for identifying the 
determinants of SERINC5 that governs its antiviral activity, and its counteraction 
by the HIV-1 accessory protein Nef. This in turn may provide molecular targets 
for the design of new ART regimens that may enhance the host intrinsic immunity 
to HIV-1 infection.   
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